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Abstract 
Human Respiratory Syncytial Virus infects the vast majority of children under the age of 
two and reoccurs in adulthood. It is a serious global problem as severe infection and 
death can result in the very young or very old and in immunocompromised people. The 
related bovine Respiratory Syncytial Virus is a serious problem for the farming 
community. To date, there is no effective treatment for Respiratory Syncytial Virus 
infection, with drugs only available to reduce symptoms in the most severe cases. 
Human Respiratory Syncytial Virus produces 10 proteins carrying out a diverse array of 
roles for the infectivity of the virus. Despite this there is still a poor understanding of the 
three dimensional structure. Only two proteins have been resolved to atomic resolution, 
the Nucleocapsid protein and the Matrix protein. The objective of this thesis is to initiate 
work on a further two proteins, with the long term aim of crystallisation studies that may 
lead to high resolution structures. The Fusion transmembrane glycoprotein is 
responsible for the fusion of the virion membrane to the host cell membrane for viral 
entry and for the fusion of an infected cell membrane to membranes of healthy cells, 
spreading infectivity. Without the Fusion protein there is no infectivity and it is therefore 
a therapeutic target. Structural information such as a high resolution X-ray crystal 
structure is required to facilitate the design of inhibitors that could be future therapeutic 
agents. The second protein studied here is the M2-1 protein, which is a transcriptional 
elongation factor, involved in replication of the viral genome. Deletion of M2-1 has 
adverse affects on the replication of the virus. Therefore M2-1 could also make a 
strong target for drug design. This thesis explores what is currently known about each 
of these vital proteins, the advantages in inhibiting their respective activities and the 
possible routes to effective inhibitor design. Procedures for expression and purification 
of the M2-1 protein are detailed here, as are preliminary experiments into the cloning 
and expression of the Fusion protein in insect cells. Immunofluorescence experiments 
into the localisation of the Fusion protein within mammalian cells and the possible 
interaction of the Fusion protein with the Matrix protein are thoroughly described.  
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Chapter One: Introduction  
 
1.1 Introduction to Respiratory Syncytial Virus 
Respiratory Syncytial Virus, RSV, affects many different species of vertebrates 
including humans (hRSV) and cattle (bovine RSV). By the age of two years of age 
most human infants are seropositive for RSV. Recurrent infection is common in later 
life although usually produces less severe infections. RSV is a leading cause of upper 
respiratory tract infections, with bronchiolitis and severe pneumonia in cases where 
infection spreads to the lower respiratory tract.1 There are an estimated 64 million 
cases a year globally, but most healthy adults when infected only suffer mild infections 
with symptoms similar in severity to a cold. However in very young infants (< 6 months 
of age), the elderly and those who are immunocompromised, the virus can cause 
severe disease and 160,000 deaths a year world-wide are attributed to hRSV.2 An 
extreme case is in those needing a bone marrow transplant- if infected by hRSV the 
mortality rate increases to 90 %.2 Importantly bovine RSV results in large agricultural 
economic losses.3 Therefore research into drugs or vaccines against both bRSV and 
hRSV is highly important. This includes research ongoing into the viral structure and in 
particular knowledge of the individual proteins hRSV produces. The various proteins of 
hRSV enable effective infection, and they also affect and interact with each other to 
facilitate replication. It is therefore pertinent that structural information on hRSV 
proteins is developed to enable an effective treatment or vaccine to be developed. 
Currently the only treatment available to control the symptoms is the drug Ribavirin, 
which only controls symptoms and is given only in the most extreme cases when other 
options have been exhausted. This is because the drugs developed so far are simply 
not effective enough, or there is little evidence to their efficacy other than control of 
symptoms.  
There is a huge range of potential patients who could benefit from effective treatment 
directed against RSV if it were available, stretching from preventing the infection in at 
risk groups via vaccine, to stopping progression in already infected patients and 
improving the outcome of a severe infection. However, the lack of structural knowledge 
of most of the proteins of hRSV is potentially limiting the progress in drug development. 
With knowledge of the 3D structure, preferably from crystallographic data for full length 
proteins, potential drug binding sites can be identified and the mode of action of the 
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protein’s functionality could be made clearer, leading to unambiguous information on 
drug mechanism of action.  
1.2 RSV- A Member of the Paramyxoviridae 
RSV is a member of the order Mononegavirales, family Paramyxoviridae, subfamily 
Pneumovirinae and genus Pneumovirus. It is therefore related to Newcastle Disease 
Virus, Measles, Human Parainfluenza Viruses and the increasingly threatening Nipah 
and Hendra viruses.4 
1.2.1 Structure of hRSV 
hRSV has a negative sense, single stranded non-segmented genome i.e. one RNA 
molecule makes up the viral genome of 15,222 nucleotides.5, 6 All four taxonomic 
families in the order Mononegavirales have a similar arrangement but varying numbers 
of genes and sizes of genome, shown in Figure 1.1 below.2  
 
 
Figure 1.1: Diagram of the Order Mononegavirales including families (blue), approximate 
genome size ranges for each family, genera (purple) with subfamilies (green) and appropriate 
examples.  
Bornaviridae 
Bornavirus (BDV) 
8 kb 
5 genes 
5 proteins 
Rubulavirus (MuV, SV-5, NDV) 
Henpavirus (Hendra, Nipah) 
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hRSV is an enveloped virus and contains a helical nucleocapsid. The virion, the 
extracellular virus particle, can be imaged using an electron microscope, showing both 
spherical and filamentous morphologies.4  
1.2.1.1 The hRSV virion 
Figure 1.2: A) Viral filaments B) Spherical viral particles. Immunoelectron 
microscopy of the F protein in Vero cells infected with the Long strain of 
hRSV for 48 hours. The glycoproteins can be seen spiking out from the 
virions’ surfaces. Adapted from T.L. Gower et al. 2005 Figure 6
7 
 
A B 
 
 
 
 Matrix Protein 
Fusion 
Protein 
Nucleocapsid 
Small 
Hydrophobic 
Protein 
Phosphoprotein 
Glycoprotein 
Large 
Protein 
Figure 1.3: Diagrammatic representation of the virion of hRSV including 
locations of the viral proteins. The virion plasma membrane is shown in 
blue. 
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The basic structure of the virion, shown schematically in Figure 1.3, follows the basic 
structure of the order Mononegavirales; there are variation in sizes, shapes and 
individual components between virions from the families.8 The RSV virion membrane is 
taken from the host cell and contains the viral glycoproteins, F, G and SH. An important 
feature in the diagram is the proteinaceous layer of M protein underneath the viral 
membrane. The presence of M is vital to viral assembly and morphology, and this layer 
also provides protection for the virion.8 Paramyxoviridae virions are pleomorphic, 
occurring as spheres or filaments, but other members of the Mononegavirales are 
different, such as the bullet shape of the virions of the Rhabdoviridae or the filament 
virions of the Filoviridae.8 The nucleocapsid consists of N protein encapsulating the 
viral genome and the holo-nucleocapsid is formed when L, P, M2-1 and M2-2 proteins 
associate with the nucleocapsid.  
For the budding process from the host cell membrane the Matrix protein, the 
glycoproteins and the nucleocapsid are required but the individual interactions are not 
yet completely clear and are largely beyond the scope of this project. The interaction of 
F and M will be discussed however. It is worth noting, that F requires M in order to 
relocate from the basolateral membrane to the apical membrane and likewise M 
appears to need F in order to be stabilised in structures in the membrane such as lipid 
rafts.9 The crux of studies into M’s function in RSV virion assembly is that presence of 
M is an essential condition for viral assembly and the layer of M beneath the 
membrane forms the spherical or filamentous shape of the virion.9 
1.2.1.2 The genome of hRSV 
The viral replication process is similar for all (-) strand RNA viruses. The RNA 
polymerase (L and P proteins in the nucleocapsid) synthesises multiple mRNAs from 
the individual cistrons, commonly referred to as genes, of the non-segmented genome. 
The transcriptase recognises specific start and stop signals that flank the individual 
cistrons in order to create individual mRNAs that are identical to “normal cellular” 
mRNAs. The proteins are then translated from the mRNAs; some RNAs are translated 
to make more than one gene product by alternate translational mechanisms.2 
Glycoproteins are then processed in the ER and Golgi and transported to the plasma 
membrane. The genome’s replication occurs by the synthesis of a complementary 
genome, the antigenome, to act as a template for synthesis of the genome. The 
genome and antigenome, unlike the viral mRNAs, are encapsidated in the 
nucleocapsid comprised mainly of N protein.  Naked genome/antigenome RNA is non-
functional even in the presence of the viral polymerase. Therefore the replication 
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process requires viral protein synthesis as it is dependent on the supply of N protein to 
form the nucleocapsid. When enough viral proteins have formed, the production moves 
from mRNA production to antigenome formation to produce templates for genomic (-) 
RNA synthesis.4 The one difference between the replicase and the transcriptase is that 
the replicase does not contain the M2-1 protein. Other than this the proteins involved in 
formation of antigenome and the proteins involved in formation of mRNA are 
identical.10 The viral genome enters into the host cell via a pore created by fusion 
proteins protruding from the virion surface, a vital process to infectivity and one which 
will be explored in detail in this introduction. 
hRSV has important differences to many of the members of its own family. It encodes 
more genes than any other member of the Paramyxoviridae and also produces more 
proteins, see Figure 1.4 for the layout of the genome. However, most of these proteins 
have equivalents in other family members.  
 
1.2.2 Proteins of hRSV 
The 11 proteins produced by hRSV include three surface glycoproteins that project out 
from the membrane as spikes. The NS (non-structural) proteins have a role in 
suppression of the immune response.2 The G protein (glycoprotein) is a 
transmembrane protein responsible for attachment to the host cell.12 It has no 
sequence or structural homology to other Paramyxoviridae members’ attachment 
proteins, such as the H (Haemagglutinin) from Measles Virus or HN 
(Haemagglutinin/Neuramidase) from Mumps Virus. A second transmembrane 
glycoprotein of the virus is the SH (Small Hydrophobic) protein - its role in viral 
replication is unknown. It is not needed for attachment or fusion and so is unimportant 
for infectivity in vitro.13 In vivo, however, the SH is important in pathogenicity as it down 
regulates apoptosis in infected cells.14 The third surface glycoprotein is the F (Fusion) 
protein which is in contrast vital for infectivity as it mediates fusion of the viral and 
cellular membrane to allow entry of the nucleocapsid. hRSV also codes for a few 
      N P M    G F M2 L 
 139 124  391    241  256  65   299     574    M2-1:194/M2-2:90   2166 
SH
H 
NS1 NS2 
3’ 5’ 
Figure 1.4: The genome organisation of hRSV, 3’ to 5’ due to the minus-strand RNA. The number 
of amino acids in each gene segment is shown underneath.  
SH 
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transcription factor proteins (M2-1 and M2-2). N, the nucleocapsid protein, 
encapsulates the viral genome interacting with L (Large Protein that carries out the 
enzymatic activity) indirectly via P (the Phosphoprotein needed in RNA synthesis).4, 15, 
16 Together the L and P form the RNA-dependent RNA polymerase (RdRp). The M 
(Matrix) protein has been a focus of many recent studies showing that it forms a 
proteinous layer underneath, and in contact, with the viral membrane. M also has a role 
in inhibiting host cell transcription and viral RNA synthesis, before packaging occurs for 
virion formation, by associating with the nucleocapsid.4  
Protein Location in the Virion Function 
NS1 and NS2,  
Non-Structural 1 and 2 
Host cell cytoplasm-not 
packaged in virion but 
synthesised in infected cells 
Suppresses innate immune 
response 
N, Nucleocapsid Nucleocapsid Encapsulates viral genome 
P, Phosphoprotein Nucleocapsid Part of the polymerase 
M, Matrix Layer on inside of membrane Involved in virion assembly 
and has a protection 
function 
SH, Small Hydrophobic Membrane Unknown 
G, Glycoprotein Membrane Attachment to host cell  
F, Fusion Membrane Fusion of virion and host 
membrane and fusion of 
infected cells’ membranes 
(syncytia)  
M2-1 Nucleocapsid and polymerase 
complex (transcriptase) 
Anti-termination factor 
M2-2 Nucleocapsid and polymerase 
complex 
Transcription factor 
L, Large RNA Polymerase complex Enzymatic activity of the 
polymerase 
 
 
1.2.2.1 Summary of Current Structural Knowledge 
The atomic structure of the Matrix protein is relatively well understood compared to 
other proteins of RSV. The crystal structure of M was determined in 2009 to a 
Table 1.1: Proteins of RSV 
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resolution of 1.6 Å by Money et al.8 The crystal structure of the Nucleocapsid protein 
was determined in 2009 to a resolution of 3.3 Å by Tawar et al.11 
In terms of potential drug targets, the F protein and the M2-1 protein would be the most 
effective. Inhibiting F would prevent viral entry, whilst inhibiting M2-1 could inhibit viral 
replication. However, these are two of the proteins for which there is very little 
structural information currently, as discussed below. 
1.3 The Role of F: Fusion 
The most useful protein for drug targeting is the third transmembrane glycoprotein- the 
F (Fusion) protein. The Fusion Protein is responsible for fusion of viral and host cell 
membranes. Without this step, viral entry into a host cell cannot occur. Therefore if an 
effective inhibitor to F can be found, and successfully developed into a drug, the virus 
could be stopped in its tracks. This has been a successful strategy with the Human 
Immunodeficiency Virus fusion protein gp41, as there is a fusion inhibitor drug 
(Enfuvirtide) used in antiviral treatment. Enfuvirtide consists of a peptide, T20 based on 
the C-terminal heptad repeat of gp41, which inhibits fusion.17 Second and third 
generation fusion inhibitors based on T20, such as the more potent inhibitor T-1249, 
are now being developed to overcome problems of resistance as well as to increase 
potency. The development of Enfuvirtide and its analogues has demonstrated that 
fusion protein inhibition can be successful and lead to anti-viral drug development.17, 18, 
19
 
The role of the F protein is to bring host and viral membranes into close proximity and 
induce fusion. Another function of F is to fuse an infected cell with neighbouring non-
infected cells. This produces multinucleated structures of giant cells called syncytia, 
enabling the spread of infection without the production of extracellular virions.20  
Out of all the proteins that hRSV codes for, the F is the one that is absolutely essential 
for viral entry into a host cell. Its function is not dependant on any other of the proteins, 
though it was previously thought that hRSV F would need activation by the attachment 
protein G.5, 21 In other members of the Paramyxoviridae the attachment protein, H or 
HN, is needed for binding to cell receptors and in activating F.22 However, this was 
found not to be the case for RSV. Studies on hRSV mutants that did not produce G or 
SH proteins, but did produce F, resulted in productive infections.21, 23 But without the F, 
viral infection could not occur even in the presence of the other viral proteins.23 
However fusion was enhanced to maximum efficiency only when all three of the 
transmembrane glycoproteins were present.12 It is also the F protein, along with the G 
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protein, that stimulates an immune response resulting in the symptoms of harbouring 
the virus.24  
F, a type-1 membrane protein shown schematically in Figure 1.5, is anchored to the 
membrane at its C-terminal end,25 has a mass of 67 kDa (574 amino acids) and is 
synthesised as an inactive precursor, F0.
25 At the C-terminus, there is a cytoplasmic tail 
(discussed in section 1.3.3). In the mature, membrane-associated virus, the CT is 
located in the interior of the virion, and it is adjacent to the transmembrane domain 
(TMD) that spans the membrane. For the protein to mature, F0 is cleaved into shorter 
polypeptides at two target motifs comprised of basic amino acid residues, The two 
cleavage products F1 (50 kDa) and F2 (10-22 kDa), are then linked by a series of 
disulphide bridges, whereupon the protein becomes functional due to the exposure of a 
hydrophobic peptide sequence, the Fusion Peptide, at the N-terminal of F1.
25 The F2 
subunit has been observed to be 22 kDa, 16 kDa or 10 kDa (the latter only present in 
Vero cells), due to observed differences in N-linked glycosylation, discussed in section 
1.3.4.26 The two stage cleavage event, at amino acid residues 106-109 (site I) and 131-
136 (site 2), in which a short intervening peptide is excised from F, is unusual as the 
norm in the Paramyxoviridae  is for a single event to expose the fusion peptide.27 The 
cleavage events in RSV, as for other paramyxoviridae  F proteins, are performed by a 
furin-like protease in the trans-Golgi apparatus.25 The cleavage occurs late in the 
transport to the membrane to prevent premature fusion of membrane components of 
the cell from  killing the cell.  
The peptide that is excised during the processing of F1 and F2 (residues 110-136, 
referred to as Pep27) is thought to have a role in stimulating the immune response to F 
and therefore hRSV.22, 28  
CT 
 
 F0 
F1 F2 
Figure 1.5: Diagrammatic representation of the F Protein, including the 
cytoplasmic tail (CT), the transmembrane domain (TMD), the two heptad 
repeat regions (HR1 and HR2), the fusion peptide (FP) and the signal 
peptide (SP).  
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As aforementioned, F1 has a C terminal hydrophobic transmembrane domain (TMD) 
which is embedded in the viral membrane, anchoring the protein.12 The rest of the 
protein, without the TMD or CT, makes up the extracellular domain.21 A second 
hydrophobic region is the glycine-rich, 20 amino acid long, Fusion Peptide at the N-
terminus of F1, which fuses to the host membrane during viral attachment.
1, 12
 The two 
heptad repeats (HR1 and HR2), present in all paramyxoviridae fusion proteins, are 
important in the process of maintaining F’s conformation in the process of fusion (see 
section 1.3.6.1). F2 holds a third heptad repeat from residues 53 to 100, although 
evidence so far suggests this is unimportant for functional integrity outside of the 
correct folding of the protein as a whole.29 F2 carries the Signal Peptide (SP) at the N-
terminus, which controls translocation of the protein into the ER, where it is removed by 
signal peptidase.26  
1.3.1 Disulphide Linkage of F1 and F2 
In active form, post-cleavage, the RSV F protein has fifteen cysteine residues,22 which 
is more than any other Paramyxoviridae member, for example, the closely related 
Measles virus fusion protein has 10 cysteine residues.24, 31 Human Parainfluenza Virus-
3 F has been used to model the molecular structure of hRSV F for study into their 
conserved cysteine residues. These are also conserved within Paramyxovirinae, such 
as NDV (which has 12 cysteines conserved between strains) and Sendai virus and 
other viruses of the Pneumovirinae such as Pneumonia Virus of Mice (PVM) and Avian 
Pneumovirus (APV).25 It has been shown by N.D. Day et al. in 2006, that by mutating 
these residues individually to serine, that ten are crucial for proper folding and 
translocation of F to the cell surface.25 The expression was reduced to 7 % of normal 
levels and the fusion activity was also greatly reduced or did not occur at all.25 Three of 
the residues when mutated to serine did not alter folding or function. This was notable 
due to the conservation of these cysteines in different Paramyxoviridae viruses, which 
would indicate they are necessary to function. Two cysteine residues within F2, 
residues 37 and 69, were shown to be extremely important in correct folding of F. 
When these were separately altered to serine the resulting fusion activity was 
negligible.25 Cysteines 37 and 69 are therefore vital to folding of the protein. Cys439 
and Cys37 are interestingly only conserved amongst pneumoviruses and not with F 
proteins from the other Paramyxoviridae subfamily the Paramyxovirinae. It is probable 
that the residues that form the disulphide linkages between F1 and F2 are Cys37 to 
Cys439, and Cys69 to Cys212.25 This conclusion has come from the comparison of the 
mapping of disulphide bridges in Sendai Virus and the conservation of these cysteines 
within other pneumovirus fusion proteins.25 If so, then the second disulphide bridge 
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(C69-C212) would be unique to the Pneumovirinae as two residues are not conserved 
amongst all Paramyxoviridae fusion proteins. Therefore the cysteines of the F protein 
are crucial to folding and consequently to function, and their inactivation can clearly 
significantly reduce, or even completely eliminate, fusion activity and so infection. 
1.3.2 The Transmembrane Domain 
The transmembrane domain of F has been found to have an apical targeting function 
that is independent of the protein’s orientation with a role in directing the protein to the 
membrane after maturation. This role could extent to directing the virion for budding 
from the apical membrane.5 However, it was shown that none of the glycoproteins that 
hRSV produces (G, F or SH) are needed for apical membrane targeting, although they 
may make a small contribution to it, nor are they needed for the virus’s release from 
that membrane.31 N- and O-linked glycans can also act as apical sorting signals and 
sites for these occur on the F and G proteins, with the apical sorting signal on the TMD 
of F being an independent one.31 There was no effect on the targeting of the virus to 
the apical membrane when each glycoprotein was deleted in turn, and no effect either 
upon the release of the virus from the host cell.31  
1.3.3 Importance of the Cytoplasmic Domain 
The cytoplasmic tails (CT in Figure 1.5) of many of the fusion proteins from other 
paramyxoviruses have a role in fusion. Related to their function are their motifs for 
palmitoylation.32 These are motifs where fatty acids attach to cysteine residues to make 
the protein more hydrophobi, thereby stabilising the membrane/protein interaction. This 
aids processing and translocation depending upon the nature of the protein in question- 
an example could be the F protein’s transport to and insertion into the viral 
membrane.33 Palmitoylation sites are sometimes also needed in viral assembly.32, 33 
The C-terminus of hRSV F, proximal to the transmembrane domain has 26 amino 
acids, including a cysteine which is palmitoylated but this cysteine has not been shown 
to be essential for processing or activity.25, 34   
A separate study, by Oomens et al. (2006) illustrated that the entire cytoplasmic tail 
does have an important role in cellular localisation of the fusion protein. It was found 
that deleting the cytoplasmic tail reduced the number of infectious virions produced. It 
is possible that without the C-terminal domain, fusion occurs prematurely. In the 
absence of the CT the protein had a very even distribution on the cell membrane, 
whereas when the CT was present the F protein was localised on filamentous 
structures 2-10μm in length.5 hRSV was modified to express the VSV (Vesicular 
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Stomatis Virus, a member of the Rhabdoviridae of the Mononegavirales) G protein with 
its CT replaced with that of RSV F. Compared to a recombinant virus with unmodified 
VSV G protein, the virus with a F CT domain produced more progeny and more/larger 
syncytia formed.5 This demonstrated that the activity of the C terminus was 
independent of the F protein’s ectodomain. The cytoplasmic tail also mediated the 
interaction of the protein with membrane lipids and this was important for viral 
assembly. This showed that the cytoplasmic tail is necessary for proper protein 
function, not for fusion itself, but to give the correct distribution at the cellular 
membrane and so maximum viral progeny.  
1.3.4 Glycosylation sites 
F has a number of N-linked glycosylation sites. This distinguishes it from the G protein 
that has high levels of O-linked glycosylation.35 Therefore the effect of glycosylation on 
protein function can be studied separately for F and G.  In unprocessed F0, there are 
potential N-linked glycosylation motifs at Asn116, Asn120 and Asn126, close to the 
furin recognition sequences at the cleavage sites. In other fusion proteins such sites 
aid cleavage by furin-like proteases. However, in mature hRSV F these sites are not 
glycosylated, suggesting they do not have a role in processing of F.35  
In the mature protein, F1 has one N-linked glycosylation site whereas F2 has two, which 
could be important for correct protein folding.25 N-linked glycans, when formed at the 
glycosylation site in the ER, bond to nitrogen atoms on asparagine residues in either 
Asn-X-Ser or Asn-X-Thr (were X is any amino acid) motifs. These glycans attach to 
mannose cores which are then removed in the Golgi apparatus, being replaced with 
more complex glycans such as fucose (this is glycan maturation). F1’s sole 
glycosylation site is Asn500 and the glycosylation sites of F2 are at Asn27 and Asn70. It 
was shown, by McDonald et al. (2006) that Asn500 has an important role in fusion 
mediation and that Asn27 and Asn70 could have a minor role in F2’s attachment ability. 
The N-linked glycosylation was not required for cleavage of the F protein, nor was it 
required for cell surface expression or for generation of progeny.35 When Asn27, Asn70 
and Asn500 were deleted in all different combinations, there was no reduction in cell 
surface expression or proteolysis of F.36 They do, however, affect fusion in different 
ways. A mutation, Asn70Gln, increased fusion activity by 50%, but the same treatment 
for Asn27 had no affect on fusion.  When glycosylation on Asn500 was inhibited, fewer 
syncytia formed as fusion activity was reduced 100-fold. Other members of the 
Paramyxoviridae have been shown to be dependant upon such glycosylation for 
infectivity. N-glycosylation and protein processing are closely linked in most of these 
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but hRSV F is an exception due to the lack of change in cell surface expression when 
the glycosylation sites are mutated.36 The reason for the importance of Asn500 is due 
to its location in HR2, and it could be that the local structure in this region needs the 
glycan maturation in order to form properly.35 It is also the case that bRSV and hRSV 
have different glycosylation needs as the equivalent bRSV Asn500 when mutated to 
alanine prevents the protein’s expression. Compounds inhibiting glycan maturation 
could be useful in inhibiting the action of F as drug molecules, at least reducing the 
level and spread of infection.35 The compound used in this study was DMJ, an inhibitor 
with broad effect. A more specific compound would be needed to be used as a first 
lead compound for design of effective drugs.35 
hRSV F also has three other potential N-linked glycosylation sites (Asn120, Asn126 
and Asn116) that differ from all other Mononegavirales fusion protein sequences. 
These are located adjacent to the cleavage site next to fusion peptide, in the Pep27 
region, possibly to aid targeting of this cleavage site to form the mature peptide .12 
However, N-glycans have not been detected on this residues and when mutating them 
does not affect the glycosylation status of the protein.36 
1.3.5   Current knowledge of 3D structure 
Integral to the structure of F are the hydrophobic heptad repeat regions situated at 
either end of the F1 subunit. This means that each F1 subunit within the F trimer has 
two repeat elements distal to each other on the extracellular domain of F1. A 
hydrophobic heptad repeat is a sequence of residues abcdefg where the amino acids 
at positions a and d are hydrophobic, see Figure 1.6. These are referred to as HR1 (or 
HRN) and HR2 (or HRC), as in Figure 1.5.1 This primary sequence tends to fold into an 
α-helix. 37 
474 IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAVKSTT 523 
Figure 1.6: The sequence of Heptad Repeat 2. Positions a and d are in green. Note residues in 
these positions: Isoleucine, valine, leucine, phenylalanine and proline are all very hydrophobic 
and take up the majority of the a and d positions. Serine and threonine are not hydrophobic but 
are also uncharged. Lysine is hydrophilic however only appears once. 
Due to their hydrophobic nature, when two of these structures interact, their α-helical 
coils wind around each other creating a coiled-coil structure. The crystal structure of a 
complex of RSV F’s two heptad repeat regions has been solved to a resolution of 2.3 Å 
and is shown schematically below in Figure 1.7.1 The interaction of the two heptad 
repeats is integral to the function of F. Both HR1 and HR2 form trimers of their α-
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helices, and therefore both form coiled-coils. The α-helical trimer of HR2 resides as a 
coiled-coil inside HR1 peptides which are arranged in an anti-parallel manner in the 
hydrophobic grooves of HR2.1, 12  
 
 
Together the heptad repeats form a 6-helix bundle that is approximately 68Å long and 
27Å in diameter. This relates well to the structure of HIV’s fusion protein gp41 and 
other viral fusion proteins.12 Within the Paramyxoviridae the positioning of the repeats is 
highly conserved, with 270 residues between them.1 This was confirmed and expanded 
upon by crystal structure determination of the two heptad repeats as the 6-helix bundle 
but bound to a potential fusion inhibitor, TMC353121, discussed in section 7.6.38 
Figure 1.7: The 6-helix bundle of HR1 interacting with HR2 diagram adapted 
from Zhao et al., (2000).
1
 Blue represents HR1 α-helical trimer and yellow 
represents HR2 α-helical trimer
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Some structural information for RSV F can be gained from studies of other members of 
the Paramyxoviridae such as the crystal structure of human parainfluenza’s F protein, 
and from the high degree of conservation of the F proteins within the Paramyxoviridae. 
Current knowledge of the hRSV F Protein’s full structure consists mainly of the 
aforementioned structure of the two heptad repeat bundle, and a homology model.  
The homology model is based on the high resolution crystal structure determination, by 
X-ray crystallography, of the Newcastle Disease Virus F Protein combined with the 
heptad repeat hexameric bundle structure, see Figure 1.8.39 This is because the 
sections of the NDV F Protein structure that could not be solved in this study were the 
heptad repeats. Therefore these two sections of information have been pieced together 
to give a model of what the hRSV F structure should look like. However, more recently 
the full structure of NDV-F has been solved, including the structures of the NDV F 
heptad repeats, and this can now be compared to the homology model and analogies 
made with RSV-F.29, 40 Comparing the two NDV F structures, the major difference is the 
inclusion of the hexameric bundle but over the whole structure there is very little 
difference. The root mean square difference between them, referring to the α-carbon 
atoms of 340 residues, being 0.74 Å.40 The small differences come in the loop 
regions.40  
Likewise there are crystal structures that have been obtained for hPIV3 and SV5 fusion 
proteins, and due to their close relation with RSV F in terms of function, the structure 
and mode of action of RSV F can be partially elucidated from this information. Class 1 
viral fusion proteins tend to be similar in terms of structure and modes of action but not 
as much so in terms of sequence, and thus such comparisons should be treated with 
caution.41, 42, 43 For example, the sequence identity between NDV F and hPIV3 F is only 
29 %, with 47 % sequence similarity, and with PIV5 these figures rise slightly to 34 % 
and 52 % respectively, which are reasonably high.40 The full crystallographic structure 
of post-fusion NDV F (resolution to 3.5 Å, slightly lower than for the previous partial 
structure) shows many general structural similarities with that of hPIV3 fusion protein, 
with minor differences attributable to the differences in their sequences. The main part 
of the PIV5 fusion protein structure that corresponds well with NDV F and hPIV3 is that 
of the heptad repeat hexameric bundle structure, this protein core is well conserved in 
the viral fusion proteins and would seem to be extremely important for their functional 
integrity.40, 43 Charge distribution studies comparing these three known structures 
indicated a huge similarity between them, which is again surprising given the low 
sequence homology. The stalks are generally negatively charged and the three trimer 
lobes in each are positively charged- the conservation of such a pattern indicates that 
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the function of the lobes lies in facilitating the interaction of the protein with the plasma 
membrane.40 
Due to the large number of structural similarities between the current structures of 
class I viral proteins and the fact that NDV F was used to create homology model of 
RSV F, this review will concentrate upon NDV F. Out of the three viral fusion proteins 
that already have a solved structure, RSV F has moderately higher sequence identity 
with NDVF than that of PIV5, with 13.5% compared to 12.4%, and only slightly lower 
than that of hPIV3 at 17.2%.44 
 
The NDV F protein structure study revealed the protein’s organisation to consist of 
three regions described as a head, a neck and a stalk. In the head, each monomer of F 
shows an immunoglobulin-type β-sandwich and highly twisted β-sheet. As with the 
Figure 1.8: Homology model of RSV F based upon X-ray crystal structure of 
the hexameric heptad repeat bundle combined with partial X-ray 
crystallographic structure of NDV F. Adapted from Morton et al. 2003.
39
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structure of the heptad repeat regions for RSV, the second crystallographic structure of 
NDV F confirmed the hexameric bundle structure to be present as the stalk. Interesting 
features to note are the three radial channels through the head and one central, 50Å 
long, central channel. These channels provide the method of exposure of the fusion 
peptide during conformational change and protein activation. When inactive, the fusion 
peptides are sequestered in the radial channels.12   
The NDV protein F has identical function to hRSV F. Their morphology is likely to be 
highly similar as they have important structural and sequence features in common.39 
This implies a homology model would be a useful tool. However, the partial NDV F 
protein structure used for the model was only solved to a resolution of 3.3 Å and the 
sequence homology between NDV F and RSV is below 15 %, below the recommended 
threshold for creating a homology model.12 Their sequence identity is only 13.5 %, as 
they are from different subfamilies. The homology model was also only of the active 
conformation of the protein. There are regions of the two F proteins where the 
secondary structure was predicted to be different and therefore the model is even more 
unreliable in these regions, particularly regarding disturbances to the predicted 
secondary structure of the heptad repeats. 12 
F protein presents as a homotrimer consisting of three units of the F1-plus-F2 entity.
25 It 
has been shown to be relatively thermostable because it is highly helical.25 Alpha 
helices and especially coiled-coils are highly thermostable due to the large amount of 
intra- and interchain hydrogen bonding involved.  Oligomerisation into a homo-oligomer 
occurs within the rough ER, before cleavage by proteases into F1 and F2. 
12, 24 
1.3.6 Relating 3D structure to function 
1.3.6.1 Fusion 
It is likely that the mechanism by which F acts to bring the two membranes together is 
a conformational change largely involving the F1 domain. This causes the protein to 
fold into a horseshoe conformation bringing the TMD (attached to the viral membrane) 
and the Fusion Peptide (attached to the host cell membrane) into juxtaposition (see 
Fig. 1.8). 
Studies into the structure of the heptad repeat regions indicated that the HR1 and HR2 
interact, forming a 6-helix bundle that stabilises the protein. It could be the case that for 
the protein to be fully functional, these two regions must bind making the active protein. 
This would occur only when they were sufficiently close, after the conformational 
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change has begun.  It is thought that a number of fusion proteins in close proximity 
form a fusion pore though which the nucleocapsid can enter the host cell.45 
Studies on other members of the type I fusion protein family (such as HIV-1 gp41, gp2 
of Ebola virus and F1 of SV5, HA of Influenza virus) support the hypothesis of the 
hairpin structure and the role of the HR stabilising the fusion complex. It is unknown 
whether the hairpin structure forms before fusion or simultaneously with it.1 By analogy 
with HIV-1 gp41, the protein could take one of three conformations depending on the 
stage of fusion. There is great structural similarity between the protein cores of gp41 
and RSV F. The inactive state is the protein where the heptad repeats are not bound in 
the hexameric bundle and the conformational change has not yet occurred, the pre-
active state would be when the conformational change has occurred but HR1 and HR2 
are not bound and the active conformation would be when the heptad repeat regions 
are fully bound in a heterodimer and the two hydrophobic regions are in the ideal 
position for the membranes to fuse (see Fig. 1.8). With gp41, in the pre-active 
conformation HR1 is exposed and the fusion peptide inserts itself into the host cell 
membrane.1 The active conformation is the fusogenic hairpin that holds the two 
membranes together.1 If either of the pre-active or inactive conformations could be 
prevented from progressing into the active conformation then membrane fusion and 
therefore viral entry could be also prevented. The deep groove of the HR1 trimer could 
be a promising drug target due to it having a hydrophobic cavity at its C-terminus and 
many hydrogen bond acceptors and donors. This would give strong binding ability for a 
drug molecule.1 
This model of gp41 in different conformational stages during the fusion process agrees 
with the appearance of RSV F when observed by electron microscopy. Anchorless, full-
length uncleaved F0 presents as unaggregated cone-like structures anchorless. Fully 
cleaved and partially cleaved (at site I not yet at site II) mature F presents as 
aggregated rosettes of lollipop-shaped spikes.27 It is only anchorless, cleaved F that 
presents as rosettes.27 Cleaved mature F always presents as aggregated cones or 
aggregated lollipop spikes due to interaction between their stalk regions.46 The protein 
only aggregates when it has been cleaved at both site I and site II. If the anchorless 
protein is cleaved with trypsin at both sites, it aggregates into rosettes of lollipop 
spikes. This is likely to be due to the interactions of the exposed fusion peptide trimer 
(as this is the only remaining hydrophobic domain). This change in shape reflects the 
change in activation of the F protein, with the unaggregated cones being the pre-active 
form and the lollipop spikes being the active form.28, 47 The lollipop shape is achieved 
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via transference of the HR2 from the neck and upper stalk to the stalk’s base during 
conformational change, diminishing the protein’s width from cone to lollipop.46 
The obvious problem with the current crystallographic structure studies on RSV F is 
that none have dealt with the full length protein, or even the anchorless protein. The 
only structure that has been successfully crystallised and solved is that of the two 
heptad repeat peptides bound to each other (see Figure 1.7).1 This is not fully 
representative of the structure of the protein in its active conformation as most of the 
sequence is missing from the structure and this absence could greatly affect the mode 
of their binding. It is clear that realisation of the full protein structure would provide a 
much greater level of information to design potential F inhibitors. Also, solving the two 
bound repeats does not give any indication of the structure of the inactive 
conformation. So far this has only been inferred from the NDV-F homology model, EM 
images of F and analogy with gp41’s mode of action. It would be most useful to obtain 
structures of all conformations of the protein (inactive, pre-active and active) in order to 
obtain a complete picture of its mode of action.  
1.3.6.2 F stimulates the immune response 
Neutralising antibodies act against F and G proteins but the two strains of hRSV, A and 
B, are defined by differences in the interaction of F with these antibodies. G is the 
same in both strains.24 There are three or four antigenic sites located on F. Antigenic 
sites IV, V and VI are located close to HR2, next to the cysteine rich region. Antigenic 
site II (not to be confused with furin cleavage site II) is at the N terminal of F1, at the 
opposite end of the cysteine rich region. Therefore this region may be important for 
antibody recognition.24 These antigenic sites are similar to those of the F proteins of 
NDV, Sendai and parainfluenza.24 The homology model based on NDV F does concur 
with known antigenic site positions of RSV F, which is another indication that it is a 
good fit. Site I is close to the crown of the head and IV, V and VI are at the pinnacle of 
the trimeric structure within the head. 
1.3.6.3 F and species specificity 
The hRSV F Protein is also one of the elements that decide the virus’ species-specific 
entry into host cells.5 It was expected that it would be G, in its job of first attachment, 
that would control species specificity. However it is likely that G simply attaches to 
surface glycosaminoglycans (GAGs) as it is not species specific.22 It is in fact F2 that is 
the determinant. GAGS do not have to be present for F to bind. Chimeric proteins of 
hRSV and bRSV F1 and F2 showed that only when F2 of hRSV was present did the 
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virus infect human cell lines of peripheral blood lymphocytes. When F2 of bRSV was 
present the virus infected bovine cell lines.22 The chimeric proteins were still functional 
in the opposing cell line due to the homology of 83 % between the two F proteins, but 
were less efficient. Therefore another importance of F has been illustrated and another 
incentive to inhibiting its action found. It is likely that F interacts with more specific cell 
surface receptors than GAGs, after G has bound non-specifically.22 Both bRSV and 
hRSV F can also bind heparan sulphate on the cell surface, and so F also contributes 
to the non-specific binding.22 This could contribute to its ability to carry out viral entry 
without the presence of the G protein. hRSV can successfully enter non-human cell 
lines but cannot replicate in them. A study by P.J. Branigan et al. in 2005 on feline, 
equine, avian, bat, canine and other vertebrate cell lines showed that F can carry out 
fusion of non-human cell lines. However, GFP labelling of mRNA revealed that the 
virus does not replicate in any of these cell types and therefore specificity is mainly 
determined post-entry. The fusion protein may use less specific or highly conserved 
cell surface receptors, or the virus may be able to enter cells using a number of 
different mechanisms.48 This considered together suggests that although F2 does have 
a role in species specificity between bRSV and hRSV, there are other factors, 
dependant on species, controlling the ability of the virus to replicate inside the host cell. 
1.3.7 The importance of lipid assemblies in fusion 
The relative importance of the action of lipid assemblies versus the actions of proteins 
in fusion processes is subject to debate. The protein has the stored conformational 
energy, assembles the closed lipid bilayers, alters conformation, stabilises unstable 
lipid structures and forms the fusogenic conformation to allow fusion. Obviously the 
form of the lipid bilayers of host and viral membrane is an important aspect of fusion 
but whether a change in the bilayer assembly occurs first to allow membrane fusion 
(lipidic pore hypothesis), or whether a protein drives the change first (protein pore 
hypothesis) is uncertain.49 The interaction of the F protein TMD and Fusion Peptide 
with the bilayer is, in either case, crucial to fusion. The fusion pore is created with the 
coming together of an unknown number of fusion proteins, when the fusion proteins are 
in their active conformation and fused with both the virion and the host cell membrane. 
They bring the two membranes together and at a point between the fusion proteins, the 
two membranes fuse creating a long “stalk” and then a flat hemifusion diaphragm, 
where the outer leaflets of the membranes fuse, with increasing tension. Finally, this 
increasing tension from the pulling of the fusion proteins causes the diaphragm to 
break apart resulting in the fusion pore via which the nucleocapsid can be transferred 
into the host cell.45 Lipid rafts are important because the interaction between the Fusion 
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Protein and the plasma membrane occurs at lipid rafts in the membrane. F targets the 
virion to these lipid rafts for budding, and does not require any other surface protein to 
do so. The target signal within F that controls this is not located in the C terminal or 
TMD nor does it involve modification of residues with fatty acids. The domain is within 
the extracellular portion of F. It may be that assembly and budding occurs at lipid rafts 
as they provide a domain for the proteins to localise to.50 
1.4 The Role of M2-1: Transcription 
M2-1 proteins are present in all pneumoviruses. hRSV M2-1 is a 194 aa, 22,150 Da 
cofactor of the viral RNA polymerase complex that acts as an elongation factor, more 
accurately an anti-termination factor.3 It is not involved in replication but is essential for 
transcription.3 It enhances read-through at gene junctions and therefore promotes long 
mRNA synthesis. This means it prevents termination occurring at stop signals. It 
therefore enables transcription to fully complete and has been implicated in the 
transcription-replication switch, though its mere presence in the ribonucleocapsid 
complex with L and P does not facilitate this switch.51 It is found in both phosphorylated 
and dephosphorylated forms.52 It has a predicted zinc finger domain at its N terminus, 
essential for its function.52 
 
 
 
1.4.1 M2 mRNA encodes M2-1 and M2-2 
M2-1 is encoded by one of two ORFs contained within the M2 mRNA (see Figure 
1.10). ORF-1 encodes M2-1 and a second ORF overlaps and encodes M2-2. This 
evolutionary mechanism for producing the most number of proteins with the smallest 
possible genome RNA also occurs in PVM and APV.53 In PVM, not only does this occur 
with the M2-1 protein but the gene for the P protein also contains a second ORF.54 All 
other transcriptional units of RSV are monocistronic and have highly conserved start-
stop sequences.6  
3’ 5’ 
835 
10 595 
563 
M2-1     194aa M2-2        90aa 
Figure 1.10: The two overlapping open reading frames of the M2 gene segment 
Oligomerisation ZnF P and RNA interaction Disorder 
Figure 1.9: Functional domains of the M2-1 protein. 
N C 
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M2-2 interestingly inhibits mRNA synthesis, acting as a transcriptional regulator, and 
has also been implicated in the replication-transcription switch but it is unnecessary for 
viral replication.54 It has been noted that low levels of both M2-1 and M2-2 gives 
transcriptional processivity but high levels of both together results in inhibited RNA 
synthesis. Removal of M2-1 reduces yield of RNA (both genomic and anti-genomic), by 
significantly reducing replicative efficiency.54 M2-1 takes up 70 % of M2’s coding 
capacity. ORF 2 overlaps at the 3’ end of M2 by 4, 6 or 10 amino acids dependant 
upon the initiation codon used in translation of M2-2.6, 53 Relocating M2-2’s initiation 
codon downstream of M2-1’s termination codon resulted in failure of M2-2 expression- 
thus the size of the overlap is essential for regulating levels of M2-2.6 M2-2 translation 
occurs by ribosomal reverse translocation. The ribosome translates M2-1 reaching its 
stop codon.53 The overlap region redirects the ribosome back upstream to the start of 
the ORF2 start codon.53 This process is significantly more effective for RSV M2-2 than 
that of PVM or APV.53 The region that controls the level of expression has been shown 
to be a very stable region with a high degree of secondary structure, a pseudoknot, 
located 150 nucleotides upstream of the overlap.53 
1.4.2 M2-1 is an RNA binding phosphoprotein 
M2-1 interacts primarily with viral mRNA for transcriptional anti-termination activity,  
and the interaction between M2-1 and N is mediated by RNA binding.3 M2-1 is able to 
bind RNA with high affinity but binds to long RNAs (with 700 to 1300 nucleotides) with 
little or no sequence specificity. 51, 52  This would indicate a structural function similar to 
the chromosomal histones, like the Nucleocapsid protein’s protection function.42 M2-1 
is also able to bind the 5’ end positive sense antigenomic RNA leader sequences (42 
nucleotides long) on segments of short RNAs (up to about 80 nucleotides) with high 
specificity. The RNA binding ability is regulated by phosphorylation. 28, 51 The RNA 
binding domain of M2-1 is located at its N terminus, mainly between residues 59 to 85. 
Phosphorylatable residues Thr56, Ser58, not contained within the general binding 
region, and Ser61 have been implicated in the changes in M2-1’s phosphorylation 
status and therefore in turn binding affinity for different RNAs.51 Ser58 and Ser61 are 
located at the end of the oligomerisation domain, at the surface of the structure.3 When 
Thr56 and Ser58 residues are mutated, the binding affinity of M2-1 to long RNAs 
decreases considerably.51 This could be due to phosphorylation status but also may be 
down to alterations in the protein’s conformation caused by the substitution. It was 
hypothesised that the differential phosphorylation alters binding affinity and that binding 
specificity for the different lengths of RNA and leader sequences may be due to 
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specific binding by different oligomers of M2-1.51 A third potential contribution to 
differential binding could be the long RNAs holding more non-specific binding sites 
simply due to their length.51 It has been experimentally determined that phosphorylation 
of M2-1 results in a 5 to 10-fold decrease in long RNA binding affinity, supporting the 
first hypothesis.6 M2-1 is mainly dephosphorylated in infected cells with a minor 
proportion of phosphorylated form present.3 
It is residues 59-85 that bind RNA and within these it has been shown that 59-62 may 
be sufficient for binding.6, 51 Sequence conservation between residues 59 and 80, 
comparing human and bovine RSV M2-1, is 95% suggesting an important conserved 
function. The region within residues 70 to 80 is predicted to be a β-sheet, whilst 
residues 50-62 are predicted to form an α-helix. Such structures exist in other RNA 
binding domains of RNA binding proteins. Thr56 and Ser58 account for 96-98% of M2-
1’s phosphorylation, with other sites contributing a small amount. The residues 85 to 
194 are not required for RNA binding.51 
An important part of the structure of M2-1 is a C3H1 binding motif at the protein’s N-
terminus between residues 7 to 25.6, 51 This is highly conserved within the Pneumovirus 
genus and in many other proteins this motif has been shown to bind zinc.51 In some 
viral proteins including HIV gp41, Zn fingers interact with RNA.51 However, when the 
putative Zinc Finger of M2-1 (the first 30 amino acids of the protein) is deleted it results 
in a surprising increase in binding affinity to long RNAs.6 Direct binding to RNA by the 
zinc motif has not yet been found to be the case for any member of the 
Paramyxoviridae.3 However, a role in regulation of M2-1’s phosphorylation has been 
demonstrated. Deletion of this zinc finger motif results in inhibition of M2-1’s 
phosphorylation therefore it is necessary for phosphorylation to occur, and therefore 
needed for proper function of M2-1.3, 55 This also correlates with the relationship 
between increased phosphorylation and decreased RNA binding affinity. The Zn finger 
motif in HIV-1 gp41 has been shown to interact with the viral RNA in order to facilitate 
tight encapsidation, which could be the case for M2-1.51  
M2-1 has four conserved cysteine residues and three of which are located within the 
Zn binding motif.6 Replacing C7, C15 and C21 reduces mRNA processivity whereas 
replacing the cysteine residue not within the C3H1 motif, C96, does not have a notable 
effect.6 C96 is therefore non-essential although it has been shown to stabilise the 
conformation of the RNA binding domain. This was shown during studies into 
electrophoretic mobility of wild type versus C96G M2-1 suggesting that the 
conformation was altered by the substitution and that C96 is involved in a disulphide 
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bond, in addition to the replication of a virus containing the M2-1 C96G mutant being 
decreased.3, 6 The mutated protein was able to co-precipitate with N indicating that the 
interaction with N was unaffected.6  
The N-terminal thirty amino acids of M2-1 were used to make a chimeric protein with 
the C-terminal domain from the PVM M2-1 protein.56 This chimera maintained normal 
activity in hRSV but the opposing chimera (with 29 amino acids from the PVM M2-1 N-
terminal with the C-terminal from RSV M2-1) had less than 5 % of normal activity; this 
showed unequivocally that the N-terminus is essential to function, at least in RSV.56 
The motif is necessary for read-through activity and phosphorylation status but its 
precise role is currently only vaguely defined.3 Leu16 and Asn17 have also been 
shown to be essential for function.3, 56 Some zinc fingers bind macromolecules, such as 
other proteins, instead of nucleic acids. For example, Ebola VP30 is an anti-termination 
factor like M2-1 that holds a Zinc finger not directly binding to RNA.3 It could be that it 
aids formation of dimers and other oligomers or else it could aid in intramolecular 
interactions helping to correctly fold the protein and holding the protein in a stable 
conformation, as with the RNA binding domain.3  
1.4.3 Interactions with proteins of the nucleocapsid 
The Zinc finger is vital for the interaction of M2-1 with the N protein.3, 57 Substituting C7, 
C15, and H25 showed that this motif is necessary for interaction with the nucleocapsid. 
3, 51
 The interaction with the nucleocapsid is moderated by M2-1-viral RNA interactions.
3 
It should be noted that phosphorylation status does not affect the nucleocapsid 
interaction.3 In infected cells, M2-1 is seen to associate in inclusion bodies containing 
N, P and L and this interaction with proteins of the holonucleocapsid complex is vital for 
M2-1’s function in transcription.3  
Phosphorylation of P at Thr108 releases the M2-1 protein from P; consequently M2-1’s 
read-through activity is lost.3, 58 M2-1 interacts with P via a helical domain between 
residues 53 and 177, the same region within which M2-1 binds viral RNA.3 If RNA is 
present, M2-1 will preferentially bind RNA over P. Since P and RNA are both negatively 
charged, this suggests a competitive binding mechanism for positively charged sites on 
M2-1, these sites having a higher affinity for RNA. Alternatively, a conformational 
change could occur once M2-1 has bound RNA meaning P is unable to bind. It has 
been shown by Tran et al. (2009) that without P being expressed, M2-1 is largely 
phosphorylated. Comparing this with the usual state of dephosphorylation in infected 
cells indicates that P interacting with M2-1 may affect phosphorylation.3 P protein is 
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important because it interacts with the L protein, which needs P to act as a cofactor in 
order to act as a polymerase during RNA synthesis. L is able to interact with the 
nucleocapsid using interactions L-P-N-RNA. N cannot encapsidate RNA during 
replication without P interacting with it.58 The switch between replication and 
transcription may be down to the phosphorylation state of P at Thre108. When 
phosphorylated, the protein is in the viral RdRp complex and cannot bind M2-1 and 
replication is carried out. When P Thre108 is dephosphorylated, M2-1 can interact with 
P, therefore M2-1 is now also in the complex, promoting transcriptase activity instead 
of replicase activity.58 P residues L101, Y102 and F109 are needed for the interaction 
with M2-1.58  
Furthermore, M2-1 also directly interacts with the final 110 amino acids of the Matrix 
protein’s N terminus.3, 59 M associates with N and P in inclusion bodies only if M2-1 is 
present.57, 59 There is potential for creating inhibitors of the M2-1-M interaction in order 
to prevent viral assembly.59 
1.4.4 The C-terminal domain of M2-1  
The heterogeneous nature of M2-1 proteins’ C termini does indicate that this region 
has little importance for function. Deletion of 47 amino acids from the C-terminus of 
M2-1 prevents full mRNA synthesis and results in a failure to produce viable viral 
progeny.6 C-terminal domains originating from different viral M2-1 proteins have 
different lengths and the shortest (that of PVM) is 17aa shorter than the A2 strain of 
hRSV; these 17 aa can be removed with little consequence to the protein’s read-
through function but reducing efficiency of viral replication by up to 60%.6, 56  
1.4.5 3D structure knowledge 
Knowledge of the 3D structure of M2-1 is, just as for to the F protein, very limited. It is 
simple to define the M2-1 protein in four sections: zinc finger, oligomerisation domain, 
globular α-helical domain (binds P and RNA) and the C terminus, see Figure 1.9.3 
Sections of secondary structure have been predicted. Circular dichroism results 
indicate that M2-1 is mostly α-helical. M2-1 is known to form globular 7.6 nm diameter 
tetramers of approximately 89 kDa.3 Oligomerisation occurs via residues in the region 
32-63: deleting this region gives greatly reduced replicative efficiency. The region 35-
58 is highly conserved within the family and consists of regular hydrophobic and polar 
residues on the same face of the helices. It is indicative of an amphipathic coiled-coil. 
Even with a GST or His tag attached, M2-1 will form oligomers. This indicates that 
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oligomerisation of M2-1 is vital for full functional ability.3 Phosphorylation of M2-1 does 
not affect its ability to oligomerise.3  
1.5 Conclusion 
There has been a great deal of information collected on the viral proteins encoded by 
hRSV, their biological activity and on the viral genome, its replication and transcription. 
Their purposes are well defined and yet their structures remain unknown. Structural 
information is available on related proteins so analogies can be made and preliminary 
structural studies have provided an insight as to their possible mechanisms. However, 
without full structures to a high resolution of a viral protein, designing inhibitors is much 
more difficult, especially given the trial and error nature of drug development, the only 
option being to construct a screen based on its biological activity. Another hurdle to 
gaining the full structure of F is the hydrophobic fusion peptide in the middle of the 
sequence, which would have to be synthesised chemically and characterised 
separately due to difficulties in purification. Preferably it would be incorporated into the 
rest of the protein.  Therefore if eventually the structure of the RSV F is solved, it may 
merely be an important part of the jigsaw puzzle and it may well take many years to 
directly design an inhibitor to fit the structure and many more years to develop it. The 
same can be said of M2-1, and with its multifunctional mechanisms this structure may 
be even more complex to decipher. The full complexity of either protein’s mode of 
action cannot be completely understood until full crystallographic structures are 
obtained.  
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Chapter Two: Production of the Fusion Protein 
 
2.1 Cloning of FSol using the Baculovirus Expression System 
Work on the fusion protein sought to clone, express and purify the soluble construct 
FSol. FSol is the extracellular domain of the F1 component of the Fusion Protein, which 
does not include the TMD or the Fusion Peptide. Previously, bovine RSV F protein has 
been successfully expressed; including using a baculovirus vector in Sf9 cells.60 A 
baculovirus system was used as early as 1989 to express the Fusion protein without 
the C-terminus, but has not been successfully purified.61 The protein is only partially 
soluble and therefore the aim of this project was to create a soluble construct to be 
used in further analysis and crystallisation. A second aim was to begin synthesis of the 
Fusion Peptide separately by chemical methods. The work on the synthesis of the 
Fusion Peptide is described in Chapter Five. 
The original cloning and expression strategy aimed to clone the full FSol ORF and 
express the protein in the Invitrogen Baculovirus Expression System.62 Using Sf21 
insect cells to express the protein should result in most post-translational modifications, 
such as glycosylation, that normally occur to give functional F protein. The strategy has 
two stages.  First we need to construct a vector expressing FSol fused at the amino 
terminus to a honey bee melittin export peptide which will promote the secretion of 
FSol into the extracellular medium.  The cloning will also result in the addition of a 
histidine tag to the carboxy terminus to facilitate downstream purification.  This protein 
construct will then be transferred to a baculovirus shuttle vector ready for insertion into 
a baculovirus. This would involve initially cloning the FSol ORF into the vector 
pMIB/V5-His, in frame with the melittin and His tags, and then subcloning into the 
FastBacTM vector. Whilst the pMIB/V5-His vector can itself be transfected into insect 
cells for protein expression, expression levels are up to 10-fold higher using the 
Baculovirus expression system.63 The system of choice is the Bac-to-Bac cloning kit.62  
In this the generation of a recombinant virus genome is performed in bacteria by 
homologous recombination between a bacmid (baculovirus genome modified with a 
plasmid origin of replication and antibiotic resistance marker to allow replication in the 
cell as a plasmid/cosmid) and a shuttle vector with our target sequence. 
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2.2 Materials and Methods 
General Materials 
All restriction enzymes and buffers were obtained from Fermentas with the exception of 
Sma1 and its appropriate buffer Buffer J, which were obtained from Promega. All 
polymerase enzymes (Platinum Pfx, Pfu, GoTaq) and buffers were obtained from 
Invitrogen. TOPO cloning kits were obtained from Invitrogen. The pFastBacTM vector 
and baculovirus stock were obtained from Invitrogen. All primers were obtained from 
Eurofins MWG Synthesis GmbH and diluted with deionised sterile water to a 
concentration of 100pmol/µl before use.  Blue/Orange 6x agarose gel DNA loading dye 
was obtained from Promega. 1kb Generuler DNA ladder was obtained from Fermentas. 
NuPage LDS 4x sample buffer (NP0007) protein loading buffer was obtained from 
Invitrogen. The Biorad Precision Plus Unstained protein ladder was used throughout. 
T4 DNA ligase and buffer were obtained from Invitrogen. Liquid S.O.C. medium (2 % 
Tryptone, 0.5 % yeast extract, 10 mM sodium chloride, 2.5 mM potassium chloride, 10 
mM magnesium chloride, 10 mM magnesium sulphate, 20 mM glucose) was obtained 
from Invitrogen.  
LB growth media: 10 g Tryptone, 10 g Yeast and 5 g NaCl in 1 L of distilled water. This 
was autoclaved for sterility.  
Ampicillin was employed at a final concentration of 100 µg ml-1 (stock 100 mg ml-1 in 
water). Chloramphenicol was employed at a final concentration of 34 µg ml-1 (stock 34 
mg ml-1 in ethanol)  
Instrumentation 
Boeco M-24OR Microcentrifuge  
Beckman Coulter AvantiTM J-20XP centrifuge 
Techne TC-312 Thermocycler 
BDH TFX-40M UV gel visualiser 
Olympus IX71 immunofluorescent microscope, 10x objective lens 
 
2.2.1 LB/Agar Plates 
5 g Agar was added to 300 ml LB media and autoclaved to dissolve the agar for 
pouring, and for sterility. The appropriate amount of the necessary selecting antibiotic 
was then added when the agar solution was cooled below 50 °C and plates poured. 
2.2.2 Growth and maintenance of SF21 cells 
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Sf21 insect cells were maintained from stock in TC100 medium (Gibco), 10 % FCS and 
antibiotic penicillin/streptomycin (50 U penicillin and 50 µg streptomycin per millilitre) 
and incubated at 26 °C. Cells were routinely spilt 1 in 10 when they reached 
confluence. As Sf21 are largely non-adherent, the flask was tapped until the cells 
detached from the surface of a flask into 10 ml of fresh medium, 1 ml was added to a 
fresh flask containing growth medium. To prepare frozen stocks for long term storage: 
cell were detached from a 75 cm2 flask as before, pelleted at 300 x g for 3 minutes and 
resuspended in 10 ml TC100 + 10 % v/v DMSO. 1 ml was pipetted into each of 10 
cryo-tubes and frozen over night at -70 °C before long term storage at -150 °C 
2.2.3 Transformation of chemically competent cells 
The primary expression vector, pMIB/V5-His (Invitrogen) was transformed into 
chemically competent cells and plated onto ampicillin selective plates as detailed 
below. The secondary expression vector for expression by baculovirus, the pFastBacTM 
vector, was transformed into chemically competent cells and plated onto ampicillin 
selective plates in the same manner.  
All steps were undertaken on ice and quickly where possible. Competent cells (TOP10, 
Invitrogen) were defrosted on ice. 2.5 µl (0.25 ng) plasmid DNA was placed in 1.5 ml 
Eppendorf tube on ice and 50 µl competent cell solution added. This was incubated for 
30 minutes on ice, then heat-shocked for 90 seconds in a water bath at 42 °C. The 
tube was then left for 2 minutes on ice and then 1 ml LB (without antibiotics) was 
added. This was incubated for 45 minutes at 37 °C then 100 µl and 200 µl of the 
solution were spread onto LB/agar plates. These were incubated at 37 °C overnight. 
Background plates were incubated for comparison.  
2.2.4 Agarose gels 
All agarose gels were made with 1 % (w/v) agarose in TAE (242 g Tris base, 57.1 ml 
glacial acetic acid, 100 ml 0.5 M EDTA (pH 8); made up to 1 L with distilled water) 
buffer stained with ethidium bromide. All samples were loaded using 1 volume of 
Promega blue/orange 6X loading buffer to 5 volumes of sample. They were run at 120 
V, constant current, for 30 minutes.  
2.2.5 Primer design 
The primers were designed as shown in Appendix B and contained restriction enzyme 
sites (in bold).  Synthesis was undertaken by MWG (Germany).  When received the 
primers were resuspended in deionised water at a final concentration of 100 pmol µl-1. 
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2.2.6 PCR amplification 
1 µl containing ca. 20 pg of template DNA was added to a reaction mix consisting of 5 
µl 10X Buffer, 1 µl reverse primer, 1 µl forward primer, 1 µl dNTP mix and 35 µl 
deionised water. Finally 1 µl (ca 1 unit) Phusion DNA polymerase was added and the 
reaction tube placed in a thermocycler (Techne). The programme used for the PCR 
was as follows: Preheat to 95 °C; Initial denaturation 95 °C 1 minute; followed by 30 x 
cycles of Denaturation 95 °C 1 minute, Annealing 60 °C 30 seconds, Extension 72 °C 2 
minutes; Final Extension 72 °C 5 minutes.  Reactions were maintained at 4 °C until 
they could be stored at -20 °C or analysed on a 1 % agarose/TAE gel. 
2.2.7 PCR product purification 
PCR product purification was performed using the QIAquick PCR Purification kit.64 
Briefly, the protocol used was as follows: 5 volumes of Buffer PB were added to 1 
volume of the PCR product and mixed. The sample was transferred to a QIAquick spin 
column in a 2 ml collection tube and centrifuged at 14,000 x g for 1 minute in a 
microfuge. The flow-through was discarded and 0.75 ml Buffer PE (wash buffer) was 
added and centrifuged for 1 minute. The flow-through was discarded and the column 
was centrifuged again for 1 minute to dry. The column was placed in a clean 
microcentrifuge tube and DNA eluted by the addition of 50 µl Buffer EB or 50 µl 
deionised water. This was left to stand for 1 minute, and centrifuged for 1 minute to 
acquire the eluted DNA. 
2.2.8 Mini-plasmid purification 
Bacterial cells from a 5-10 ml overnight culture were harvested by centrifugation for 3 
minutes at 5000 rpm in a benchtop centrifuge at room temperature and plasmid DNA 
isolated using the QIAprep Spin Miniprep Kit (Qiagen).65 Briefly, the pelleted bacterial 
cells were resuspended in 250 µl Buffer P1 and transferred to a microcentrifuge tube. 
250 µl Buffer P2 (lysis buffer) was added and the tube was inverted 6 times to mix until 
a homogenously coloured solution is obtained. 350 µl Buffer N3 (neutralising solution) 
was added and the tube was inverted 6 times to mix and the solution became cloudy. 
The cell debris was pelleted by centrifuging at 13,000 rpm for 10 minutes. The 
supernatant was transferred to a QIAprep spin column and centrifuged for 1 minute. 
The flow-through was discarded. The column was washed with 0.75 ml Buffer PE and 
centrifuged for 1 minute, the flow-through was discarded and the tube was again 
centrifuged for 1 minute to ensure all wash buffer was removed. To elute the DNA the 
QIAprep column was placed in a clean microcentrifuge tube and 50 µl Buffer EB or 50 
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µl deionised water was added to the column. This was left to stand for 1 minute and 
centrifuged for 1 minute to acquire the eluted DNA.  
2.2.9 Restriction enzyme digestion of DNA 
Restriction of DNA (plasmid or PCR fragment) was performed as follows:  Assuming a 
20 µl reaction volume to DNA in water, 2 µl of the appropriate 10 x buffer was added 
and 2 µl (5-10 units) of the enzyme or enzymes (1 + 1 µl), if a double digest was being 
performed, added.  Deionised water was added to adjust to a final volume of 20 µl.  For 
different volumes the amounts were adjusted so that a 1 x buffer concentration was 
maintained as well as an appropriate enzyme to DNA ratio.  The reactions were 
incubated for 3 hours at the recommended temperature, often 37 ºC. Plasmids used in 
cloning experiments were dephosphorylated by the addition of CIAP (calf intestinal 
alkaline phosphatase) during the restriction digest 
2.2.10 Gel extraction for restriction product purification 
Restricted DNA fragments were purified using a gel extraction kit from Qiagen.64 DNA 
was resolved by agarose gel electrophoresis and excised using a scalpel whilst 
visualised under UV light.  
The DNA-gel fragment was weighed and place in a microcentrifuge tube.  To the 
fragment 3 gel volumes (100 mg gel ~ 100 µl) of buffer QC (solubilising buffer) was 
added and this was incubated at 50 °C for 10 minutes until the gel was completely 
dissolved. 1 gel volume of isopropanol was added and the tube mixed. The solution 
was transferred to a QIAquick spin column in a 2 ml collection tube, and centrifuged for 
1 minute. The flow-through was discarded and 0.5 ml Buffer QG was added to the 
column. This was centrifuged for 1 minute and the flow-through discarded. 0.75 ml of 
Buffer PE (wash buffer) was added to the QIAquick column and this was centrifuged for 
1 minute. The flow-through was discarded and the column centrifuged for another 
minute to ensure all wash buffer was removed. The column was placed into a fresh 
microcentrifuge tube and to elute DNA, 50 µl Buffer EB or 50 µl deionised water was 
added and the tube centrifuged for 1 minute to obtain the DNA. 
2.2.11 Alternative gel extraction protocol 
The DNA was excised from the agarose gel using a scalpel, ensuring full coverage of 
hands, neck and face due to use UV for visualisation and the fragments were dissolved 
in 600 µl Binding Buffer (6 M sodium perchlorate, 50 mM Tris-HCl pH 8.0, 10 mM 
EDTA). To this, 10 ul 166 mg ml-1 silica in water was added and this was incubated at 
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room temperature for 30 minutes. The suspension was then centrifuged at 12, 000 x g 
for 30 seconds.  The supernatant was removed and the pellet was re-suspended in 200 
µl Binding Buffer. This was centrifuged again and the pellet was re-suspended in 750 µl 
Wash Buffer (400 mM NaCl, 20 mM Tris-HCl ph 7.5, 2 mM EDTA and 50% (v/v) 
ethanol). This was repeated. Then the suspension was centrifuged, supernatant was 
removed and the pellet left to dry in the air for 30 minutes. The pellet was re-
suspended in 15 µl deionised water and this was incubated at 37 °C for 15 minutes. 
The sample was then centrifuged at 12,000 g for 2 minutes and the supernatant 
containing DNA was removed and stored at -20 °C. 
2.2.12 Ligation 
Into each of two PCR tubes was pipetted 10 µl restricted pMIB/V5-His (ca. 100 ng) and 
4 µl 5X Ligase Buffer. 5 µl (50 ng) insert DNA was added, giving a insert: vector ratio 
between 3:1 and 5:1. To the control tube (background vector ligation) 5 µl H2O was 
added in place of the insert DNA. The reactions were heated to 65 °C then cooled to < 
30 °C at which point 1 unit of of T4 Ligase was added and the reaction incubated at 14 
°C for 16 hrs.  
2.2.13 Ethanol precipitation  
This was only necessary if using electroporation for transformation of electro-
competent cells to concentrate and desalt the ligated DNA in order to avoid an 
electrical arc.  
The ligated DNA was transferred to a 1.5 ml Eppendorf tube and 1/10 vol Sodium 
Acetate (pH 5.5) was added. This was mixed and 2.5 volumes of 100 % ethanol were 
added. 1 µl seeDNA (GE Healthcare) was added in order to visualise the DNA when 
pelleted. The solution was incubated at -20 °C for at least one hour followed by 
centrifugation at 13,000 rpm for 30 minutes at 4 °C.. The supernatant was removed 
and the DNA was visualised as a red pellet. The pellet was washed with cold 70 % 
ethanol and centrifuged at 13, 000 rpm for 3 minutes. The liquid was removed and the 
DNA allowed to air dry. The DNA was then suspended in deionised water or 
appropriate buffer if needed. 
2.2.14 Electrotransformation 
All steps were performed on ice. Electrocompetent Escherichia. coli XL-1 blues (a gift 
from Dr R. Dorazi), were thawed on ice for 15 minutes. 4 µl ligated DNA in deionised 
water was added to a new 1.5 ml cold Eppendorf tube to which 40 µl of electo-
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[32] 
 
competent cells was added. This was transferred to a cold electroporation cuvette (0.2 
gap, BioRad), placed in the electroporator and an electric pulse with the following 
settings: voltage 2.5 kV, capacitance 25 F and resistance 200 . A pulse time of 5.8 
msec indicated a successful pulse.  1 ml warm S.O.C. media was added to the cuvette 
and transferred, with the transformed bacteria, to a universal and shaken for 1 hr at 37 
°C then 100 µl and 200 µl were spread onto LB/agar plates with ampicillin. These were 
incubated at 37 °C overnight until colonies developed. 
2.2.15 Colony PCR  
Colonies obtained after transformation were screened for successful ligation of insert 
into the plasmid by colony PCR. A 500 µl PCR reaction solution was made up: 250 µl 
2x GoTaq polymerase enzyme reaction mix (includes dye for visualisation on agarose 
gels), 230 µl H2O and 10 µl of each primer and split into 25 µl aliquots in PCR tubes. A 
numbered grid was drawn on a fresh LB/agar ampicillin selective plate. Colonies to be 
tested were numbered similarly and a pipette was used to streak each colony onto the 
appropriately numbered square and then spot them into the appropriately numbered 
PCR tube. The ligated DNA product was used as a positive control. The samples were 
subjected to PCR programme was as follows: Primary denaturation 5 minutes 95 °C; 
30X cycles: denaturation 30 seconds 95 °C, annealing 30 seconds 58 °C to 43.5 °C 
(temp decrease by 0.33 °C/cycle), extension 1 minute 72 °; final extension 10 minutes 
72 °C. Reactions were maintained at 4 °C until they could be analysed on a 1 % 
agarose/TAE gel. 
2.2.16 Topoisomerase cloning of FSol 
2.2.16.1 Ligation and transformation with the Invitrogen Champion TOPO Kit 66 
To facilitate TOPO cloning (a ligase free system) PCR (1 µl) products were added to 3 
µl deionised water, 1 µl salt solution, and 1 µl TOPO vector. This was left for 5 minutes 
at room temperature. 3 µl was transferred to a tube containing chemically competent 
TOP10 cells (Invitrogen) on ice for 30 minutes followed by heat-shocking at 42 °C for 
45 seconds. This was then left on ice for 2 minutes to which was added 1 ml warm LB 
and incubated at 37 °C for 45-60 minutes. 100 µl was then spread onto a LB ampicillin 
plate.  
2.2.16.2 Ligation and transformation with the Zero Blunt® TOPO® PCR Cloning 
Kit for Sequencing 67 
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This kit did not require the specific end on the primer necessary for the previous 
Champion kit. The protocol in the manual for using the Invitrogen Zero Blunt TOPO 
PCR Cloning kit was used.67 For a 6 µl reaction: 4 µl PCR product, 1 µl salt solution, 1 
µl Zero Blunt pCR4®Blunt-TOPO® vector were mixed and this was incubated at room 
temperature for 5 minutes. This solution was transformed into commercial DH5α-T1R 
One Shot® Chemically Competent cells from the kit, a summary of the protocol follows. 
6 µl of reaction mixture was transferred to a tube containing One Shot® chemically 
competent cells and mixed. This was incubated on ice for 20 minutes. The cells were 
heat-shocked at 42 °C for 30 seconds then transferred immediately to ice. 250 µl pre-
warmed LB medium was added and the tube was shaken for 1 hr at 37 °C.  200 µl and 
20 µl were spread onto 50 µg/ml kanamycin selective LB/agar plates, which had been 
pre-warmed to 37 °C and coated in X-gal for blue/white colony selection. 
2.3 Results and Discussion 
The initial conventional cloning strategy was repeated several times (PCR 
amplification, digestion, gel extraction, ligation, transformation and colony PCR), by the 
methods detailed in section 2.2. Primers used can be found in Appendix B along with 
the sequence of the full 574 amino acid long F protein. FSol was RT-PCRed from RSV 
(strain A2) genome RNA and cloned via engineered EcoRI (5') and HindIII (3') into 
pSVZeo2+, by Dr R. P. Yeo FSol is the 499 amino acid long construct of F that does 
not contain the Signal Peptide or the TMD. 
Cloning stages analysed on 1 % agarose gels were always repeated successfully (see 
Figure 2.1 and Figure 2.2) until the ligation and transformation stages, where few 
positive colonies resulted or (in the case of the ligation into pMIB/V5-His) few colonies 
selectively grew at all. The FSol fragment is 1722 base pairs in length. The pMIB/V5-
His plasmid is 3596 nucleotides long. 
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The purified pMIB/V5-His plasmid and FSol fragment were restricted and purified by 
gel extraction, see Figure 2.2.  
  +ve               PCR  product bp 
Figure 2.1: FSol fragment as a positive control 
and the PCR amplified sample of FSol run on a 
1% agarose gel 
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Figure 2.2: pMIB/V5-His plasmid and FSol DNA fragment 
restricted with HindIII and XBa1, run out on a 1% agarose 
gel for gel extraction and purification. 
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The pMIB/V5-His plasmid was restricted in order to unwind the supercoil for viewing on 
a DNA gel and check it is the correct size using 10 µg plasmid, 10X Buffer 1 µl, 3 µl 
H2O, 5 µl Pvu1 restriction enzyme, 1 µl CIAP.  
The transformation stage was repeated using commercial chemically competent 
TOP10 cells from Invitrogen but this did not give any positive colonies upon colony 
PCR. 
It is not possible to analysis the success of the ligation stage on an agarose gel due to 
the low quantity of DNA used. Therefore effort was made to optimise these stages, 
using TOPO cloning techniques and commercial cells. Two Invitrogen TOPO cloning 
kits (Champion and Zero Blunt) were used in order to facilitate the ligation of the 
construct into pMIB/V5-His.  
2.3.1 Topoisomerase Cloning 
The principle of TOPO cloning is based upon the activity of Topoisomerase 1, an 
enzyme from Vaccinia virus that cleaves the phosphodiester backbone of one strand 
after the motif 5’-CCCTT. To conserve the energy from the breaking of this covalent 
bond, one is formed between the 3’ phosphate of the cleaved strand and the Tyr-274 of 
topoisomerase 1. This bond between DNA and enzyme is then attacked by the 5’ 
hydroxyl group of the cleaved strand, releasing TOPO isomerase and reversing the 
reaction recreating the bond in the phosphodiester backbone. This is used in TOPO 
cloning to insert in a PCR product to a TOPO vector without the use of ligase.62, 63  
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Figure 2.3: Restriction of pMIBV5His with 
Pvu1 to check the plasmid size 
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2.3.1.1 Directional Cloning: Invitrogen Champion pET Directional TOPO 
Expression Kit 66 
Directional TOPO cloning, using the Champion pET Directional TOPO Expression Kit, 
is achieved by addition of an overhang on the TOPO-DNA of GTGG and of a CACC 
sequence on the 5’ end of the forward primer required for PCR of the FSol fragment. 
The cloning vector overhang of GTGG invades the 5’ end of the PCR product, anneals 
and holds the PCR product in the correct orientation for directional cloning. The same 
reverse primer as above was used but the forward primer employed here was therefore 
altered to CACCAAGCTTACAAAACATCACTGAAGAATTTTATC (see Appendix B).  
This commercial cloning kit from Invitrogen was used, as detailed in 2.2.16.1, as an 
alternative method of cloning, (the object being to sub-clone into pMIB/V5-His and then 
express the protein in insect cells) as it should be quick (the ligation takes only 5 
minutes to react) and highly efficient for the cloning of the FSol blunt ended PCR 
product. It also does not require a ligase or use conventional ligation, a procedure 
which was thought to be a problem for FSol cloning. For this method a new forward 
primer had to be designed, in order to include the motif CACC on the 5’ end of the 
primer for directional cloning. However, attempts at using this protocol and commercial 
Figure 2.4: Representation of the 5’ OH of the cleaved strand attacking 
the DNA-enzyme bond to form the backbone between PCR product and 
vector for cloning of a PCR product. Adapted from the Champion™ pET 
Directional TOPO
® 
Expression Kits User Manual.
66
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kit with commercial TOP10 cells failed, shown by agarose gels of colony PCR negative 
results (see Fig. 2.5) and the fact there were few colonies produced (under 10 per 
attempt). 
2.3.1.2 Cloning: Invitrogen Zero Blunt® TOPO® PCR Cloning Kit for Sequencing 
67 
The likely reason of the failure in cloning FSol up till this point was due to the fact that 
ligating a PCR product alone is more difficult than when the desired gene is ligated in 
another plasmid, as it is more difficult for the ends to be located by the ligase than if 
anchored in a large plasmid. Cloning of a PCR product is notoriously difficult. Therefore 
this cloning kit was used, as detailed in section 2.2.16.2, as it optimises the ligation of 
blunt-ended PCR products to the appropriate site in the Zero Blunt pCR4®Blunt-TOPO® 
Vector. Then, this can be restricted using the appropriate restriction enzymes (in this 
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Figure 2.5: Results of colony PCR on 22 colonies from TOPO Zero Blunt 
cloning and a negative control analysed on a 1 % agarose gel.  
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case HindIII and XbaI) in order to sub-clone the gene into pMIB/V5-His. This can then 
be transferred to the Baculovirus expression system as planned.  The maximum 
amount of PCR product, 4 µl, was used in order to force the reaction to complete and 
give the maximum amount of annealed PCR fragment in vector for transformation. 
More reaction mixture than recommended (the whole 6 µl of reaction mixture rather 
than 2 µl) was used for transformation for this reason. X-gal was used to screen for 
positive colonies as the vector supported blue/white colony screening. X-gal is a non-
toxic chromogenic substance that can detect the activity of the enzyme β-galactosidase 
(that hydrolyses lactose into glucose and galactose) in E. coli as X-gal is converted by 
the enzyme into an insoluble blue compound- this allows Lac+ and Lac- colonies to be 
distinguished.68 
A band was obtained for two tested colonies on the agarose gel analysing the colony 
PCR from Zero Blunt cloning, see Figure 2.5. However this band appeared at 1000 
base pairs and not at the expected 1500 base pairs. This could be down to mis-
priming. Therefore an additional test was conducted on the DNA obtained.  
The purified recombinant plasmid was tested for the desired gene FSol by restriction 
with an enzyme (Nde1) that would restrict the insert in one place but not affect the 
Ladder      
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plasmid. It was seen on a 1 % agarose gel that the restricted plasmid from the positive 
colony appeared to contain the fragment as the DNA has been cut and linearised and 
is no longer supercoiled (appearing slightly higher up on the gel). See Figure 2.6. 
Therefore it was decided to continue to the next stage of cloning whilst awaiting 
sequencing results, and the original restriction enzymes HindIII and Xba1 were used to 
restrict the recombinant pCR® 4Blunt-TOPO® plasmid and the pMIB/V5-His plasmid for 
subcloning. 
The positive clones were sequenced using the vector M13 forward and backward 
primers. Unfortunately, the result bore no resemblance to the sequence of the fusion 
protein; this was despite the positive result of the Nde1 restriction- obviously the 
undesired product contained this restriction site. Due to time constraints a new cloning 
procedure could not be attempted but suggestions for further work are outlined in 
Chapter Seven.  
Figure 2.7: Restriction of recombinant plasmid and pMIB/V5-His with 
HindIII and Xba1 A) 1 % agarose gel of 5 fractions of cloned and 
restricted FSol in the pCR
®
 4Blunt-TOPO
® 
vector B) 1 % agarose gel 
of 5 fractions of restricted pMIB/V5-His plasmid 
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Chapter Three: Retargeting and Immunofluorescent 
Imaging of F 
 
3.1 Introduction and Aims 
The aims of immunofluorescence experiments were to image the localisation of various 
F constructs inside and on the surface of lung cells, and to ascertain at what point the 
Matrix protein and F interact with each other.  
3.2 Materials and Methods 
Materials 
α-bovine FITC antibody was obtained from Sigma Aldrich. C5335 bovine α-RSV F was a 
gift from Geraldine Taylor, Institute of Animal Health, Compton, UK. Murine α-RSV M 
antibody was a gift from Dr R.P. Yeo, University of Durham, UK and was diluted 1/3000 
for use. AlexFluor goat anti-bovine IgG was obtained from Invitrogen.  
3.2.1 Preparation of a working baculovirus stock 
Sf21 cells in a T75 flask were infected with BacF (a baculovirus expressing the full 
length F protein, a gift from P. Yeo). Typically the cells’ medium was removed from the 
cells and 10 ml fresh medium added.  BacF was added to the cells at an m.o.i. of 5-10 
and allowed infect for 30-60 minutes with an occasional tilt to ensure the cells did not 
dry out. A further 10 ml fresh TC100 medium was added to the flask. After 6-7 days, 
most of the media was removed and centrifuged at 5000 r.p.m to pellet cells and other 
debris. The supernatant, which is the virus stock, was aliquoted (1 ml) and stored at -
70 °C.  Titres of 1 x 107 ml-1 could routinely be produced 
3.2.2 Subculturing of A549 cells 
The cell medium (2 % FCS in DMEM, Gibco) was poured off and few mls of trypsin 
were added to the monolayer of cells and swirled over in order to wash the remainder 
of the medium away. This is in order to remove the Bovine Pancreatic Trypsin Inhibitor 
(BPTI) for the trypsin to be active. The trypsin was removed and a few more mls 
added, then versene was added to a ratio of 1:4 trypsin: versene. Versene contains 
EDTA that aid in the dissociation of cells from the flask. The flask was placed in the 
incubator at 37 °C for a few minutes. The solution was opaque as the trypsin began to 
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remove the cells from the flask and at this point the flask was removed from the 
incubator. 50 ml fresh media was added to the cells, dispersing them evenly throughout 
the medium. The cells were then split between fresh flasks as needed. 
3.2.3 Immunofluorescence assays 
From a stock of A549 cells approximately 1 x 105 cells in 1 ml was pipetted into each 
well of a 12 well plate. Each well also contained a 13 mm cover slip. This was 
incubated at 37 °C until the cells reach 50% confluency. The medium was removed 
using a pipette and 200 µl fresh media was added to each well. 20 µl human 
respiratory syncytial virus (m.o.i 1) was added to each well. This was left for 30-60 
minutes with an occasional tilt. 2 ml fresh media were added to each well and this was 
left 33 °C. 
After 24-48 hours the media was carefully removed and the cells washed gently with 
PBS (x3).  The cells were fixed with 0.15 % formaldehyde in PBS containing 0.05% w/v 
sucrose (19 ml PBS, 1 ml 30% formaldehyde, 0.2 g sucrose) for 10 minutes at RT. This 
was removed and washed with PBS as before. 0.5 ml permeabilising solution (19 ml 
PBS, 1 ml Tritonx-100, 2 g sucrose) was added to each well and left for 10 minutes. 
This was removed by three washes with PBS + 1 % FCS and then left for 30 minutes. 
Antibodies used and their dilutions are tabulated in Table 3.1. The primary antibody 
was added and left for 1 hr. Unbound primary antibody was removed by washing three 
times with PBS. The secondary (usually FITC-conjugated) antibody was added to each 
well and left for 1 hour after which the cells were washed with PBS three times. 100 µl 
PBS + DAPI (to label nuclei) diluted 1/1000 was added, left for 5 minutes and removed. 
Experiment Primary Antibody and Dilution Secondary Antibody and 
Dilution 
Imaging of F in A549 cells Bovine α-RSV 1/1000 AlexFluor goat anti-bovine 
IgG diluted 1/250 
Imaging of varying F 
constructs in A549 cells for 
localisation studies of F  
Pure C5335 bovine α-RSV F 
0.6 mgml
-1
 diluted 1/1000 
α-bovine FITC diluted 1/250 
Transfection of A549 Cells Pure C5335 bovine α-RSV F 
0.6 mgml
-1
 diluted 1/1000 
α-bovine FITC diluted 1/250 
Table 3.1: Antibodies and dilutions used in immunofluorescent imaging studies of F 
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[42] 
 
PBS was added to just cover the cells. The cells in the wells were viewed under an 
immunofluorescence microscope.  
3.2.4 A549 cell transfection 
A549 cells were split and transferred 1 ml into each well of a 24 well plate. Overnight 
these grew to 75 % confluence. The cells were then infected with Vaccinia TF7.5 virus 
by pipetting 15 µl of virus in 100 µl Optimem solution into each well. They were left to 
infect for one hour then washed with PBS. Transfection mix for 24 wells was made, 200 
ng of plasmid and 0.6 µl Fugene was required for each well: 100 µl Optimem per well 
was pipetted into a sterile 1.5 µl Eppendorf tube and then Fugene was added and then 
the DNA. The construct used varied as follows with 4 wells transfected with each F 
construct: FWT, FSTOP, FER, FENDO, FGOLGI, FSURFACE (see Table 3.2). 6 wells (2 of each F 
construct well) were also transfected with the plasmid DNA coding the Matrix protein. 
This was left for 30 minutes at room temperature. The correct amount of transfection 
mixture was added to each well carefully dropwise. This was left for 6-10 hours and 
then washed with PBS and fixed with formaldehyde affixing solution as in section 3.2.3. 
The plate was now safe to work on out of the Microbiological Safety Cabinet. Half of 
the cells were permeabilised with permeabilising solution and labelling with antibodies 
was carried out as in 3.2.3. 
3.3 Results and Discussion 
3.3.1 Surface Expression 
An initial experiment was successfully undertaken to visualise the mature F protein on 
the surface of A549 (lung epithelial) cell infect with RSV, see Figure 3.1.  
F protein surface 
expression 
Figure 3.1: Immunofluorescent image of A549 
cells infected with RSV and labelled with anti-F.  
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[43] 
 
3.3.1 Retargeting F to specific cellular organelles 
Constructs were obtained from Dr R.P. Yeo. These were designed to target specific 
organelles and therefore give compartmentalisation of F by including a signal sequence 
in the cytoplasmic tail of each F construct. 
Imaging experiments carried out by myself and Dr R.P Yeo were successful in showing 
the localisation of the F constructs to the different organelles they were carefully 
designed for. The FSTOP construct was full-length F protein without the C-terminal 
domain in order to ascertain whether it is the C-terminal domain that allows interaction 
with lipid rafts in the membrane. Primers were designed to insert the retention signals 
in Table 3.2. The anti-sense primers have 18 bases at the 3’ end to anchor to the target 
sequence in the early stages of PCR then the retention signal (for example KKXX, 
where X is any amino acid) motif, a stop codon and a restriction enzyme site. The 
additional 9 bases at the 5’ end are there to enhance the efficiency of the restriction 
enzyme. 
Label Construct 
FSURFACE KKAAAA 
FER KKAA  
FENDO YKGL 
FGOLGI CPSDSEEDEG  
Negative Control F KKAAAA 
Table 3.2: Constructs of the F gene used in transfection of A549 
immunofluorescence experiments 
 
The preliminary experiments used long exposure times (4 seconds) for the α-bovine 
FITC, compared to the DAPI (100 ms) and therefore the relative fluorescence levels 
seen on the pictures are unreliable and hazy. It may be that the antibody had been 
exposed to light on a previous occasion and underwent photobleaching. The 
preliminary results do illustrate that the expressed constructs were correctly locating 
either on the surface of the cell or within the cell but specific locations and organelles 
cannot be identified. See Figure 3.2. 
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Further experiments carried out using an alternative batch of antibody were successful 
and gave clear results where the localisation of the F constructs was evident. See 
Figure 3.3. From Figure 3.3d it can be seen that the construct FSTOP, which does not 
contain the cytoplasmic tail, is still localising to the membrane. 
 
 
 
(f) 
(g) (h)  
(i) (j) 
(k) (l)  
(d)  
(e) 
(b) (a) 
(c) 
Figure 3.2: Preliminary immunofluorescence of A549 cell transfections, either surface-
stained (S) or permeabilised (P) as follows: (a) FENDO S (b) FENDO P; (c) FER S (d) FER P; (e) 
FGOLGI S (f) FGOLGI P; (g) FSTOP S (h) FSTOP P; (i) FSURFACE S (j) FSURFACE P; (k) FWT S (l) FWT P 
. DAPI was used in order to stain cell nuclei, seen in blue. F protein can be seen in green. 
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Figure 3.3: Immunofluorescence images of mammalian cells infected with ( a) FER;  
(b)FGOL-END (F is recycled to the Golgi via the endosomes); (c) FGOLGI; (d) FSTOP (e) FWT (f) 
F Negative control Labelled F protein can be seen in green. No DAPI staining was used. 
Figure 3.4: Cells infected with RSV and labelled for F for 
showing viral filaments in yellow. The red signal is a 
nucleus stain called propidium iodide. 
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3.3.3 Localisation of F and M in A549 cells 
It can be seen that F did indeed interact and co-localise with M. However, it is obvious 
in Figure 3.5F that this caused massive damage to the cells when the localisation 
occurred at the membrane. In Figure 3.5H it can be seen that F and M co-localised at 
the Golgi apparatus. Therefore a new approach will be necessary, outlined in Chapter 
Seven.   
A B C 
H G F 
E D 
Figure 3.5 Immunofluorescence images of A549 cells viewed with a Ziess 
confocal microscope transfected with A) FWT P B) FWT S C)M D)FENDO E)FER 
F) FWT and M G) FER and M H)FENDO and M. F protein is seen in green, M 
protein is seen in red and colocalisation of F and M can be seen in yellow. 
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Chapter Four: Optimisation of the Expression and 
Purification of the M2-1 Protein in Bacteria 
 
4.1 Introduction and Aims 
The aim of this project was to express and purify full length M2-1 protein in preparation 
for structural analysis by circular dichroism and X-ray crystallography. The sequence of 
M2-1 can be found in Appendix B2. 
4.2 Materials and Methods 
Materials and Instrumentation 
Standard transfer unit for Western Blotting: semi-dry blotting apparatus from BioRad. 
Glutathione-sepharose beads and a 5 ml GSTrapTM FF (Fast Flow) column were 
obtained from GE Healthcare Sciences. 
Thermo Scientific NanoDrop Spectrophotometer 230nm-600 nm 
4.2.1 SDS PAGE 
To make 5 ml of resolving gel mix (12.5% polyacrylamide) mix 1.75 ml H2O, 1.25 ml 4 x 
resolving buffer (1.5 M Tris pH8.8, 0.4% w/v SDS), 2.00 ml 30% w/v polyacrylamide, 
25.0 µl 10% w/v  APS, 5 µl TEMED.  
For 2 ml of stacking Gel: 1.15 ml H2O, 0.50 ml 4 x stacking buffer (0.5M Tris pH 6.8, 
0.4 % w/v SDS), 0.335 ml 30 % w/v polyacrylamide, 15.0 µl 10 % w/v  APS, 2.5 µl 
TEMED 
A Biorad Protean III mini-gel system was employed using gel plates with 0.75 mm 
spacers.  Initially the resolving gel mix was poured into assembled glass plates until 
approximately 1.5 cm from the top.  A layer of propan-2-ol was used overlaying the 
setting gel.  This resulted in a more even junction and excluded oxygen which can 
inhibit the polymerisation reaction. Once set a layer of stacking gel was added along 
with the comb to create wells and this was allowed to polymerise. 
Samples in NuPage LDS sample buffer (Invitrogen) were boiled for 3 minutes before 
being pipetted into the appropriate wells, the first well containing unstained protein 
ladder (Promega). Electrophoresis was performed at 200 V for 45-50 minutes. The gels 
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were dissembled and the gel washed with deionised water and stained for one hour 
with Coomassie Blue staining solution (0.25g Coomassie Blue, 75 ml Glacial acetic 
acid, 500 ml methanol, water to 1L), then de-stain solution (methanol 200 ml, 100 ml 
glacial acetic acid, water to 1 L) was applied until the protein bands were apparent.. 
4.2.2 Western blotting 
1X Western Blot Transfer Buffer: 5.82 g Trizma Base and 2.93 g Glycine were 
dissolved in H2O and 200 ml methanol was added. This was made up to 1 L with 
distilled water. A 10X solution was made.  
Nitrocellulose membrane and two pieces of extra thick blotting card were cut to the size 
of the gel. These were soaked in 1X transfer buffer. Onto the standard transfer unit was 
placed in order first a piece of blotter, followed by the membrane, then the gel and then 
the second piece of blotter. A small corner was cut off the membrane for orientation. 
After assembling the semi-dry blotting apparatus (BioRad) the transfer was performed 
for 30 minutes at 15 V with a limit of 3 mA. The membrane was then transferred to a 
clean container and washed with a 2 % milk protein/PBS solution. The membrane was 
then blocked in 4 % milk protein/PBS for 1 hr followed by washing three times with PBS 
+ 0.2 % v/v Tritonx-100 solution (PBS-T). The primary antibody (anti-M2-1 Mab 312 
from mouse) diluted 1/1000 in PBS-T was added- and this was left to bind for 1 hr. The 
membrane was again washed x3 with PBS-T solution. The secondary antibody, anti-
mouse IgG Peroxidase antibody produced in goat, in PBS-T was added and left on the 
shaker for 1 hr. This was washed x3 for 5 minutes each in PBS-T.  
4.2.3 Detection by chemiluminescence 
The two components that constitute the detection reagent (Amersham ECL) were 
mixed together just before they were added to just cover the membrane and incubated 
for 1 minute and then it was blotted dry gently. In the dark room, the membrane was 
exposed to X-ray film (X-Ray Retina XBM blue-sensitive film) for 5 minutes, ensuring 
the membrane is the correct side facing the X-ray film. This was placed in developer 
solution for a couple of minutes and then placed in Fixer solution for a couple of 
minutes. Both fixer and developer solutions were Champion Photochemistry RG 
Universal Ready to Use solutions. Finally the developed film was washed in water and 
dried before recording image via a digital scanner. 
4.2.4 Production of Chemically Competent Cells 
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A scrape of frozen BL21 Codonplus (BL21C+, Novagen) cells in glycerol was obtained 
with a loop and put into a tube with 10 ml LB with chloramphenicol. This was incubated 
in a shaker overnight at 37 °C. 0.5 ml of the overnight culture was added to 50 ml 2xYT 
media (16 g Trytone, 10 g Yeast Extract, 5 g NaCl, pH 7.2) with chloramphenicol. This 
was allowed to grow for 3 hours at 37 °C with shaking. 100 mM CaCl2 (2.94 g in 200 ml 
water) was autoclaved then put on ice. The culture was transferred to a 50 ml Falcon 
tube and centrifuged for 3 minutes at 5000 rpm at 4 °C. The medium was poured off 
and the cell pellet resuspended in 25 ml ice cold 100 mM CaCl2. This was incubated on 
ice for 15-30 minutes then pelleted again in the centrifuge. The supernatant was 
poured off and the pellet resuspended in 20 ml CaCl2, then this was left on ice again for 
another 15-30 minutes. This was spun down, the supernatant poured off and the pellet 
resuspended on ice repeatedly in 10 ml, 5 ml and 2.5ml CaCl2.  
4.2.5 Transformation of BCL21C+ cells with GST-M2-1-pGEX-6.   
300 µl of competent cells were transferred into a chilled 1.5 ml Eppendorf tube on ice. 1 
µl DNA was added. This was incubated for 30-60 minutes on ice then heat-shocked at 
42 °C for 3 minutes. This was then left on ice for 3 minutes. Then 700 µl 2xYT was 
added and this was left to grow for 1 hr then 100 µl was plated on ampicillin plus 
chloramphenicol selective plates and incubated at 37 °C overnight. 100 µl was grown 
in 10 ml 2XYT with ampicillin and chloramphenicol overnight. 
4.2.6 IPTG induced expression 
1 L 2 x YT media with ampicillin was inoculated with a 10 ml overnight culture of 
transformed cells. This was left to grow for 3 hrs at 37 °C in a shaker. A 1 ml sample 
was retained for analysis. Isopropyl-D-thiogalactopyranoside (IPTG) was added to a 
final concentration of 0.2 mM -1 mM, this was permitted to grow for another three hours 
at 28 °C. A sample was taken then the culture was centrifuged at 6000 rpm for 10 
minutes at 4 °C. The pellet was stored at -70 °C.  
4.2.7 M2-1 Purification 
Purification Buffers prepared: 
 Lysis Buffer: 50 mM Tris pH, 7.5, 1 M NaCl, 2 % Triton x-100, 100 mM MgCl2, 1 
mM CaCl2, 1 mgml
-1 lysozyme, RNAase A and protease inhibitor tablets 
(Roche, Mannheim, Germany). Triton x-100 was added last after all other 
components to facilitate dissolution. 
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 PreScission Protease Cleavage Buffer: 50 mM Tris HCl pH 7.8, 150 mM NaCl, 
1 mM EDTA, 1 mM Dithiothreitol (DTT)  
 Elution Buffer: pH 8: 50 mM Tris, 10 mM reduced glutathione 
4.2.7.1 Purification using a GSTrapTM 
All steps were performed on ice or at low temperature where possible. The pellet was 
fully defrosted and resuspended in 20 ml lysis buffer (this was altered to 50 ml lysis 
buffer for purification of larger pellets) and incubated on ice for one hour. A lysate was 
prepared by sonicating the bacterial solution and removing the cell debris by 
centrifugation in a JA 25.50 rpm rotor at 20000 rpm (ca 40, 000 x g) for 15 minutes at 
4°C. The clarified lysate was filtered successively through 1.2 µm, 0.8 µm and finally 
0.2 µm syringe filters. The GSTrap FF column was equilibrated with 6 column volumes 
of deionised water followed by 6 column volumes of lysis buffer. The filtered lysate was 
loaded onto the column through the 0.2 µm filter at a rate of 4 ml min-1. The through-
flow was collected and reloaded on to the column to ensure all tagged protein had 
adhered to the column. The column was washed with 10 column volumes of lysis buffer 
followed by 10 column volumes of cleavage buffer. 20 µl PreScission Protease diluted 
in 5 ml cleavage buffer was loaded onto the column and this was left at 4 °C overnight. 
5 ml cleavage buffer was loaded onto the column and 4 fractions of 1 ml were 
collected. Elution of protease and GST was done using 10 column volumes of elution 
buffer. The column was washed using 10 column volumes each of lysis buffer, water 
then 20 % v/v ethanol in water. 
4.2.7.2 Purification using glutathione-sepharose beads 
All steps were performed on ice or at low temperature where possible. A lysate was 
prepared as described above. Glutathione beads (GE Healthcare Sciences) were 
washed three times with 3 ml PBS to remove the storage ethanol containing buffer: 1.5 
ml/litre of starting culture beads were added to the clarified bacteria lysate and allowed 
to bind for 30 minutes at 4 °C on a carousel. The glutathione beads containing bound 
proteins were collected by low speed centrifugation for 5 minutes. The supernatant was 
carefully pipetted off (as beads easily resuspend) and the beads were washed with an 
excess volume of lysis buffer (x20 volume of beads) three times followed by three 
times in cleavage buffer. At this stage a 12.5 % polyacrylamide gel was run on samples 
collected throughout the purification stages in order to check the tagged protein was 
attached to the beads. 20 µl PreScission Protease was added in 5 ml cleavage buffer. 
This was left overnight at 4 °C. The beads in solution were centrifuged at 2000 rpm for 
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two minutes. The supernatant containing the protein was pipetted into a separate tube 
and the beads were washed in cleavage buffer, collecting the supernatants for 
analysis.  
4.2.8 Anion exchange chromatography  
Buffer A: 1 L: 5.01 g 1-methyl-piperazine (volatile liquid needs a beaker with 100 ml 
water on a balance and added), 0.05 M Bis-Tris (10.46 g), 0.025 M Tris 3.03 g 
Buffer B: 1 L: 0.1 M HCL (3.65 g) 
Buffer C: 1 L: H2O 
Buffer D: 1 L: 2 M NaCl (116.4 g) 
To determine the most effective condition for anion exchange chromatography a scout 
technique was employed using a GE Healthcare ÄKTA Explorer FPLC system. Using 
the basic buffers above the system will mix each in various combinations, 
automatically, to produce buffers of varying pH and salt composition.  To start with 
protein in a low salt buffer is added to the column and sequentially the effect of 
changing the pH (6, 7, 8) on binding and elution, during a increasing salt gradient was 
tested. Chromatograms were obtained. Fractions obtained were analysed on 12.5 % 
polyacrylamide gels. 
4.2.10 Dialysis  
One 1.5 ml tube of protein in cleavage buffer was dialysed into the required buffer such 
as low salt buffer (50 mM Tris pH 7.5, 25 mM KCl, 5 mM MgCl2), PBS or deionised 
water, using dialysis buttons or dialysis tubing for volumes over 1 ml. The buffer was 
changed twice and left overnight. 
4.2.11 Protein solution concentration 
The 14 ml of the M2-1-GST containing fraction was dialysed from elution buffer into 
cleavage buffer using dialysis tubing and clamps. The solution was changed to fresh 
cleavage buffer after 3 hours and again before leaving overnight. Still in the dialysis 
tubing, this was dried gently with paper towel and placed on a pile of Polyethylene 
glycol in a deep plastic tray and then covered with more PEG. This was left for half an 
hour. Damp PEG was replaced regularly and fresh PEG was added if necessary at half 
hour intervals. This reduced the volume to 3 ml which was pipette into two Eppendorf 
microcentrifuge tubes and a sample was run on a 12.5% polyacrylamide gel.  
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4.3 Results and Discussion 
Before expression and purification of the protein, the M2-1-pGEX-6-P1 clone obtained 
from Dr R.P. Yeo was checked by restriction with the original restriction enzyme, SmaI, 
in order to establish the presence of the correctly sized M2-1 gene fragment, as in 
section 2.2.9, see Figure 4.1.  
Two approaches were used to optimise the conditions that would lead to the production 
of high quality protein suitable for high resolution structural studies such as X-ray 
crystallography. The first was to use a pre-packed GSTrap FF column and the second 
was to use glutathione sepharose beads in a batch-type preparation. The M2-1 protein 
ORF had previously been cloned into the pGEX-6-P1 vector in frame with the GST 
protein (M2-1-pGEX-6-P1). The GST and M2-1 moieties were separated by a linker 
containing a PreScission protease cleavage site, a highly specific protease based on 
the Rhinovirus 3C protease. In both approaches protein was loaded onto the 
column/beads, washed to remove non-specific binding proteins and this was followed 
by cleavage with the PreScission protease. This process released the M2-1 component 
leaving the GST tag on the solid phase. The sepharose bead method overall produced 
the purest protein, although a combination of the two techniques also produced 
relatively pure protein. This could be because the GST-protein attached more firmly to 
the column, needing a high concentration of glutathione to be eluted and cleavage was 
less efficient on the column than in solution- possibly due to reduced access to the 
cleavage site or aggregation of the protein on the column. Protease cleavage on the 
beads was simple and yeilded protein in the supernatant without GST (which was still 
Figure 4.1: A) M2-1-pGEX-6-P1 before restriction 
B) M2-1-pGEX after restriction with Sma1 
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attached to the glutathione sepharose beads). It was also possible to put the beads on 
a carousel overnight during cleavage, in order to facilitate mixing and access to the 
protein, rather than allowing the beads to settle with consequent restricted access to 
the protease in the buffer. Another advantage of the beads was they were more 
suitable for using on large amounts of bacterial cell lysate, whereas in the column it 
was necessary to dilute the pellet material down with lysis buffer in order not to block 
the syringe filters. 
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Figure 4.2: Samples taken from stages of purification of M2-1 using a GSTrap
TM
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There was initial difficulty in obtaining pure protein that did not include amounts of 
GST-M2-1 uncleaved and in eluting the GST using the column, see Figure 4.2. 
This was attributed to the amount of protease used and therefore it was increased in a 
subsequent purification. An alternative to the commercial PreScission Protease, 3C 
protease (a gift from Dr J. Flint, Institute for Cell and Molecular Biosciences, Newcastle 
University) was tried but had the same results. In addition, the culture growth time was 
extended from 3 hours 37 °C, 3 hours IPTG-induced 28 °C to 6 hours 37 °C, 16 hours 
(overnight) IPTG-induced 28°C. This gave much larger pellets containing potentially 
greater amounts of protein. At one stage, a great deal of protein was produced as half 
of the product obtained was re-cleaved with another 50 µl of protease and half was left 
alone- both fractions after 2 days displayed one band on an agarose gel indicating full 
cleavage had occurred, see Figure 4.3.  
In an attempt to further purify the protein to ensure all GST was removed the GSTrapTM 
was used but with the following alterations to protocol: 
3.00 ml protein in cleavage buffer was loaded and a 5.00 ml fraction was collected. 
5.00 ml cleavage buffer was put through the column. 10.0 column volumes of elution 
buffer were put through. The column was washed as normal. A gel was run on the 
collected fractions- the higher bands on the previous gel were removed during 
Figure 4.3: Fully cleaved M2-1 and GST 
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purification and a great deal of protein appeared to remain but the dimer GST-M2-1 
was still present in the elution fraction (some could be viewed on the comparison of the 
cleaved and uncleaved so this was to be expected). See Figure 4.4. 
Concentrations of each fraction were obtained using the NanoDrop spectrophotometer 
as follows: 1) 0.316 mg ml-1 2) 0.320 mg ml-1 3) 0.451 mg ml-1 4) 0.427 mg ml-1 5) 0.438 
mg ml-1. Four of the fractions underwent FPLC anion exchange chromatography 
purification and one was dialysed into a low salt buffer for analysis by LC electrospray 
mass spectrometry. 
However, purification by anion exchange chromatography was unsuccessful. The 
sample in LSB did not stick to the column and initial attempt with a small amount of the 
other four pooled fractions showed the protein did stick to the column and eluted at the 
highest salt concentration, favouring pH 8. The remainder of the samples were injected 
and run at pH 8; however the protein remained stuck to the column and could not be 
recovered.  
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Figure 4.4: Second purification of the cleaved protein from remaining GST 
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Purified M2-1 was analysed on a HiLoadTM 16/60 Superdex Prep Grade gel filtration 
column showing that it was present as a tetramer. This was shown by comparison of a 
calibration curve carried out with the low molecular weight (LMW) gel filtration 
calibration kit (Amersham Pharmacia Biotech Inc.), against a graph of retention times 
of the M2-1 protein solution, both shown in Figure 4.5.  On the chromatogram for the 
M2-1 solution, it can be seen there is a peak at 40 minutes. The peak at 46 minutes on 
the protein standard chromatogram corresponds to ConAlbumin, a protein with a 
molecular mass of 75 kDa. As it eluted from the column at a time extremely close to but 
prior to that of ConAlbumin, M2-1 is present as a tetramer of around 89kDa (based on 
four monomers of 22.15 kDa). To completely confirm this is a tetramer and not larger, a 
protein standard higher than 90 kDa would be needed. 
Finally, the purification protocol was done more quickly, by not waiting to run an 
acrylamide gel to check the protein was present before adding protease (as this was 
known to work). Instead, 50 µl 3C protease was added to the beads immediately and 
left for a longer period of time overnight. This produced immediately pure protein, with 
Figure 4.5: Gel filtration chromatography results using the HiLoad
TM
 16/60 Superdex Prep 
Grade gel filtration column. Blue: Chromatographic curve for retention times of protein 
solution. Red: Chromatographic separation of standard proteins. C: ConAlbumin 75kDa, 
O: Ovalbumin (43 kDa), CA: Carbonic anhydrase (29kDa), R: Ribonuclease A (14 kDA), 
A Aprotinin (6.5 kDa). 
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no other dimer or GST-Protein bands remaining on the gel see Figure 4.6. Completely 
pure M2-1 protein was obtained and made suitable for initial crystallisation studies and 
structural analysis, specifically circular dichroism analysis.  
It is worth noting whilst viewing the above gel photographs that the M2-1 protein is 
22.15 kDa, 3C protease is 22 kDa and GST is 27 kDa. Not enough 3C protease was 
used for it to be visible on a gel. Therefore on some of the acrylamide gels the GST 
and M2-1 protein are very difficult to tell apart. It should also be noted that the 
disadvantage of using homemade 3C protease instead of commercial PreScission 
protease is that PreScission also contains a GST tag which would leave it attached to 
the GST Trap or to glutathione sepharose beads. Western blot analysis had to be 
utilised in order to verify the presence of M2-1.  
Figure 4.6: Optimised purification of M2-1 on glutathione-sepharose beads 
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Western blot analysis was carried out using α-M2-1 antibody. This produced three 
bands on the film, relating to monomer, dimer and tetramer of the protein, see Figure 
4.7. It should be noted again that on an SDS page gel the dimer would appear at the 
same point as the uncleaved GST-Protein and therefore be difficult to identify. Western 
blotting is therefore necessary to determine whether GST or M2-1 is present, or both. A 
second Western blot was carried out on the same sample but this time testing for the 
presence of GST and repeated and both were negative. 
 
  
Figure 4.7: Photograph of X-ray film after 
detection by Chemiluminescence of a Western 
blot analysis nitrocellulose membrane 
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Chapter Five: Placement in Industry: Onyx Scientific and 
Peptide Synthesis 
 
5.1 Introduction to Onyx Scientific 
During this project a placement in a North East of England chemical company was 
undertaken. The partner company was Onyx Scientific, a medium sized medicinal 
chemistry business involved in the production of small molecules mainly for larger 
pharmaceutical companies. The small molecules produced at Onyx Scientific are 
usually produced there because they are difficult to synthesise, requiring first small 
scale research into the most suitable synthesis pathway. Within the company, the 
production is scaled up in stages until kilograms may be produced to a high level of 
purity.  
5.2 Aims and Objectives 
The aims of the time spent at Onyx Scientific, in relation to the research project, were 
to learn the principles and practice behind successful solution phase peptide synthesis, 
via the production of a dipeptide. This was with a view to planning and carrying out the 
synthesis of the full peptide. The dipeptide to be produced consisted of the first two 
amino acids in the sequence of the Fusion Peptide (amino acid sequence: 
FLGFLLGVGSAIASGVAVS). This is the hydrophobic peptide of the Fusion Protein that 
cannot be easily made and purified via recombinant DNA methods.  
A second and equally important aim was to gain experience of working in an industrial 
(rather than an academic) setting and to learn about the chemicals industry and 
science in business rather than in academic research. 
5.3 Introduction to peptide synthesis 
5.3.1 The stepwise approach versus fragmentation condensation 
Basically, there are two approaches to peptide synthesis. The first is to take a stepwise 
approach, adding on one amino acid at a time onto the peptide chain. The second 
method is to make short fragments of two or three amino acids via stepwise synthesis 
and then to condense them together forming a longer peptide. It is often the case with 
long peptides (>20 residues) that fragments are made using solid-phase synthesis 
techniques and then condensed together using solution-phase chemistry.  
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A tripeptide can be made in three ways: [1 + 2 + 3] versus [(1 + 2) + 3] or [1+ (2 + 3)]. 
Obviously the number of possible ways to make a peptide increases with its length. 
Therefore instead of arbitrarily assigning fragments to piece together or forging ahead 
with a stepwise approach and seeing how far one gets, there are a number of 
considerations to take into account. Firstly, that if the fragment condensation approach 
is taken there are advantages in terms of parallel synthesis- more than one of the same 
peptide but with subtle differences, such as in mutation studies, can be made in 
parallel. Likewise, if the strategy and reaction conditions are uncertain several could be 
tried on a small scale at the same time. Stepwise synthesis is, naturally, sequential and 
therefore slow, as each stage should be characterised. Also, bringing small fragments 
together to make a larger peptide means that isolation of the desired product will be 
easier at this stage, as there will be a larger difference between product and starting 
materials (compared to the starting material being only one amino acid shorter than the 
product).  
A second consideration is that some residues on the end of peptide fragments will 
allow fragment condensation more easily than others, for example glycine on the end 
of a peptide fragment would mean no steric hindrance for another amino acid binding. 
The presence of cysteines means disulphide bond formation is likely and must be 
planned around- preferably leaving them until the last possible point to add to the 
peptide and protecting them (see 5.3.2). Met or Trp should similarly be added last if 
possible, as methionine’s thioester side-chain and tryptophan’s indole ring may be 
attacked by electrophiles in acidolysis.69 Protection group choices (see 5.3.2) and 
limitation of racemisation (see 5.3.6) also make the matter more complex. The 
protection strategy used for making the fragments has to be compatible with the 
conditions used in condensation. Finally, it is always a good objective to aim for one 
final deprotection step, in which all of the side chain protecting groups are removed 
and, if solid phase synthesis is used, the peptide can also be cleaved from the resin 
cleanly.  
5.3.2 Protection group strategies 
There are a great many options to consider for developing the most appropriate 
protecting group strategy. The α-carboxy protecting group should be orthogonal to the 
α-amino protecting group used, meaning one protecting group can be removed from 
the molecule using a method that will not affect the second protecting. Orthogonality 
must also be considered when choosing side-chain protecting groups, if they are 
necessary. Ease of cleavage is an issue, as obviously it is preferable to use the mildest 
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conditions possible- a reason one might choose to use benzyl esters rather than ethyl 
esters, for example, as the latter requires strong cleavage conditions (see 5.3.2.3). 
Certain protection methods can even make racemisation less likely due to their mode 
of action.69 
Because amino acids have carboxy groups that are much more nucleophilic than their 
amino groups, peptides can be synthesised in theory without any protection at all. 
However, usually a maximal protection method is used. This is because protecting 
groups can also offer additional advantages in terms of increasing the solubility of the 
peptide and facilitating its isolation and purification.  
This introduction to protection strategies will focus on the synthesis of the Fusion 
Peptide and the advantages of the strategy used, as a broader discussion of protecting 
groups is beyond the scope of this project.  
5.3.2.1 Fmoc α-amino protection 
Fmoc (9-fluroenylmethoxycarbonyl) is stable to acidic conditions and is cleaved by 
bases, such as 20% piperidine in DMF. Using piperidine at room temperature to cleave 
Fmoc from the α-amino group of an amino acid on the end of a peptide chain takes a 
matter of seconds, though there are alternative cleavage reagents. The elimination 
reaction occurs by a E1CB (elimination conjugate base) mechanism via a 
dibenzocyclopentadienide intermediate anion. Dibenzofulvene produced as a result 
reacts with the piperidine giving a co-product in addition to the deprotected amino 
acid.69 Fmoc deprotection wouldn’t affect a Boc or a Z group on another amino acid as 
they are orthogonal groups (see 5.3.2.2). Fmoc can also be cleaved by catalytic 
hydrogenolysis.  
5.3.2.2 Boc α-amino protection 
In contrast to Fmoc, the Boc (Di-tert-butyl dicarbonate) group is stable in basic 
conditions and in the presence of nucleophiles but is very labile to acids. It is more 
labile to acids than an alternative protecting group, the Z (benzyloxycarbonyl) group, 
but is considerably more stable to base.69 Therefore, Z and Boc are orthogonal, which 
is important as this means one can be cleaved without affecting the other at different 
stages of the synthesis. Boc is removed by treatment with acid, such as TFA or HCl in 
dioxane and ether flooding. In workup of reactions involving a Boc group, the use of 
strong acids in acidification should be avoided so citric acid is usually chosen as it is 
not extracted easily into the organic phase from the aqueous.  
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5.3.2.3 Ethyl ester α-carboxy protection 
Ethyl (and methyl) esters are good protecting groups as they remain uncleaved by 
most coupling conditions and most deprotection conditions, and α-amino protecting 
groups can be removed selectively. However, one problem that can occur is with the 
use of piperidine to remove an Fmoc group. This is because dipeptide methyl or ethyl 
ester free bases can cyclise to DKPs (diketopiperazines) readily (Scheme 5.1), and this 
will occur under basic cleavage conditions used to remove the Fmoc protecting 
group.69  
 
The use of methyl esters is less favoured than using ethyl esters, as they can be 
difficult to remove when it is time to do so, needing strong conditions.  
5.3.2.4 Benzyl ester α-carboxy protection 
Preferably, the use of benzyl esters for protection should be considered instead of 
methy; or ethyl esters. Although dipeptide benzyl esters may still form DKPs under 
basic conditions, they are easier to remove than ethyl or methyl esters by 
saponification (forming an alcohol plus carboxylic acid salt under basic conditions) or 
hydrazinolysis.69 Benzyl esters cannot be cleaved with acids like TFA and therefore are 
orthogonal with Boc α-amino protection.  
5.3.3 Activation and Coupling 
In this synthesis, the coupling of two amino acids to make a dipeptide was undertaken 
by the activation of the ester group formed as the α-carboxy protecting group on 
phenylalanine. A phenol ester makes for a better leaving group than an ethyl ester, and 
this is important for the aminolysis of the ester, which occurs via collapse of a 
tetrahedral intermediate. Active esters are normally synthesised using DCCI or HBTU 
coupling reagents (see below). Side reactions and racemisation are not a significant 
Scheme 5.1: DKP formation under basic conditions 
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problem as active esters are relatively inactive before the intermediate is produced. 
However, if they are made directly and the carbonyl component is vulnerable then 
racemisation is likely, usually occurring if a base is present (see section 5.3.6). More 
reactive active esters are used more in solid phase synthesis. Active esters give 
excellent results during salt couplings (as in this dipeptide synthesis).69  
The most popular coupling reagent is dicyclohexylcarbodiimide (DCCI/DCC) for 
activating carboxy groups, such as making active esters and can be used as a direct 
coupler. The activating event is the formation of O-acylisourea, a strong acylating agent 
formed by addition of the amino acid carboxy group to the carbodiimide group, and this 
leads immediately to the peptide by aminolysis. However, the reaction via this 
carbodiimide group often results in partial racemisation. Direct coupling using DCCI 
needs only an organic solvent and equimolar amounts of each component.69  
Another class of coupling reagents are the phosphonium and “uronium” salts, such as 
the two used in the dipeptide coupling of this project- PyBop and HBTU. HBTU, O-
(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate, does not 
actually contain a uronium component as first thought, despite its name, but in fact has 
a guanidinium structure.70 The use of HBTU reduces racemisation to a minimum, and 
reactions using this coupling agent are very fast, under one hour.69 PyBOP, a 
phosphonium coupling reagent, is an analogue of the coupling reagent BOP 
(benzotriazolyloxytris-(dimethylamino)phosphonium hexafluorophosphate). BOP 
became almost as popular as DCCI despite the fact that using it runs the risk of severe 
racemisation occurring during the coupling. In this respect, HBTU is clearly superior. 
The advantage of PyBop over Bop is that it minimises the production of a carcinogenic 
side-product, hexamethylphosphoramide.69 There are now more analogues of PyBop 
available that have this advantage but that produce higher yields of coupled product, 
and likewise there are analogues of HBTU although these have not surpassed the 
original in yield or racemisation minimisation.70  
5.3.4 Solution phase synthesis versus solid phase synthesis 
Synthetic peptides were first produced using solution phase synthesis. The first fully 
biologically active peptide to be synthesised chemically using solution phase 
techniques was oxytocin (uterine contracting pituitary hormone). This was achieved by 
Vincent de Vigneaud in 1954; this beginning of modern peptide synthesis was 
recognised by his Nobel Prize the following year.71 Examples such as oxytocin peptide 
hormone and also porcine gastrin 1 are of particular significance to the field in terms of 
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development of protection strategies and fragment condensation strategies. The 
production of human insulin achieved the synthetic formation of a peptide consisting of 
two chains held together by disulphide bonds.  
Solid phase peptide synthesis (SPPS) was developed by Bruce Merrifield in the 1960s 
and is now the focus of much peptide synthesis research. The initial test of the method 
was done by synthesising a tetrapeptide in 1963.72  Within a year, the technique had 
been finely tuned for the synthesis of the nonapeptide bradykinin.73, 74 The “solid” part 
of the technique’s title refers to the resin on which the peptide is made, which consists 
of swollen gels made by solvent and solute molecules contained inside a polymeric 
matrix.72 Solid phase synthesis methods are much quicker and cleaner than solution 
phase methods, and the length of peptides being produced since the 1960s has greatly 
increased due to the development of this method. It is worth noting that the most 
successful solution phase peptide chemist, de Vigneaud, had no trouble recognising 
the benefits of SPPS, and indeed his laboratory adopted Merrifield’s new technique to 
synthesise vasopressin and deamino-oxytocin, which they famously co-authored a 
paper on in 1968.71 
There are two main SPPS methods - the original Merrifield technique or the Sheppard 
technique. Merrifield’s original concept has been finely tuned for modern synthesis. 
Polystyrene cross-linked by divinylbenzene is chloromethylated and the target peptide 
C-terminal amino acid residue (amino-protected with a Boc group) is attached to the 
matrix by nucleophilic displacement. Deprotection of the Boc group with mild acid 
allows coupling of the next amino acid by DCCI. This is repeated until the desired 
peptide is formed.71 Side chains are protected where necessary with groups that are 
not labile to the mild acid needed for Boc deprotection. Washing occurs regularly to 
remove co-products and excess reagents (the peptide-polymer matrix is insoluble). 
Strong acid (HF) at the final step removes all of the protecting groups and the peptide 
from the resin.  
Sheppard’s argument in the early 1970s was that if the polymeric matrix was 
chemically similar to the peptide being synthesised then both could be used in an open 
gel system in dipolar aprotic solvents, with free access to reactive sites.75 In Merrifield’s 
synthesis, the solvent used to swell the matrix (dichloromethane) cannot also solvate 
the peptide chain and so this encourages aggregation and, as a result, reactive site 
access is lower.75 Therefore polystyrenes were often replaced by polyamide carriers. 
Sheppard synthesis is usually carried out using Fmoc α-amino protection instead of 
Boc and the final deprotection can be under much milder conditions due to the strategy 
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of α-Fmoc combined with ω-mild acid labile groups. Merrifield α-Boc with ω-strong acid 
labile tactics are also not completely orthogonal as with the Sheppard protection.69 
The only problems with solid phase synthesis are firstly, that certain peptides form 
aggregates around the resin, therefore sterically hindering any further synthesis. 
Secondly, the level of reaction completeness needed at each stage to make a long 
peptide at high yield was simply too high. The end product can contain truncated 
sequences (if a residue remains unreacted) or deletion mutants (if an unreacted 
residue is coupled in the next coupling reaction). For example, the Fusion peptide 
requires 19 amino acids, so 18 coupling reactions. If each is 99 % complete and no 
truncated sequences occur then the end product will be comprised of approximately 19 
% impurities reflecting the 19 possible deletion sequences. However, it is possible to 
push completion to 100 % with an excess of acylating reagent and doing each coupling 
more than once.  
Modern technology such as the use of HPLC for separation and microwaves to speed 
up synthesis (not only by temperature but also by electromagnetic agitation of the chain 
to prevent aggregation), along with automation of the solid-phase process, has greatly 
increased the speed and yields of peptide synthesis compared to solution phase 
techniques, and also made it much easier for the non-chemist to synthesise a peptide 
needed for biological characterisation. This is the reason why it is advisable to carry out 
solution phase synthesis first, at least in part, if the chemistry is to be understood. It is 
most useful to be able to programme a computer to carry out the synthesis but this can 
be to the detriment of knowledge and understanding.  
5.3.5 Considerations for individual residues 
In the case of this particular dipeptide synthesis only phenylalanine and leucine need 
be considered in detail. These amino acids fortunately have limited side-chain 
functionality and therefore do not need to be protected. The only problem might come 
if, to cleave a protecting group, catalytic hydrogenolysis was used as phenylalanine 
could reduce to cyclohexylalanine.69 There are no such issues with leucine 
Other residues can cause a great deal of difficultly and their side chains will need to be 
protected during synthesis. The other residues of the complete Fusion Peptide are 
unlikely to cause difficulty but some complications are possible. Unhindered access to 
glycine residues in a peptide allows side-reactions to occur-if a peptide had a relatively 
high content of glycine then it may be insoluble and difficult to purify.  The hydroxyl 
group of serine is able to react with acylating agents so would usually be protected (for 
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example using benzyl ether subsequently cleaved by strong acidolysis) but if mild 
carboxy activation is used it may be left unprotected.69 
5.3.6 Consideration and control of racemisation 
For peptide synthesis this involves the change from one enantiomer to a mixture of 
enantiomers or partial epimerisation (where a mixture of diastereomers that differ at 
one chiral centre forms). Often, the desired product is only one diastereomer or 
enantiomer (especially in medicinal chemistry), which makes purification a problem and 
analysis slightly trickier if a racemic mixture has been formed.  
There are two main mechanisms of racemisation that occur during peptide synthesis. 
The first is direct enolisation (Scheme 5.2),69 where the α-carbon is deprotonated and 
the carbanion can then protonate on either side:  
 
The rate is dependent upon the base strength, the nature of the solvent, and the 
electron withdrawing effect of groups at the chiral centre. Racemisation is faster when 
strong electron withdrawing groups are present and with sterically unhindered strong 
bases in dipolar aprotic solvents, such as DMSO.69 However, the rate alone does not 
determine the amount of racemisation that occurs. It is a balancing act between the 
rate of enolisation and the rate of coupling and, usually, this mechanism only causes 
significant racemisation when coupling is slow.  
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Scheme 5.2: Direct enolisation 
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The second mechanism of racemisation is the formation of oxalones (Scheme 5.3). 
These form due to activated acylamino acids cyclising in basic conditions. Oxalones 
are prone to aminolysis, reacting with amino acids inducing peptide bond formation. 
But they also racemise via stabilised anions and this is unfortunately usually at a faster 
rate than coupling can occur.69 
This fast rate can be slowed if the protecting group at the amino group is an 
alkoxycarbonyl such as Boc or Fmoc (Figure 5.1), as these oxalones are quicker to 
aminolyse and racemise compared to acylamino acid oxalones.69  
 
This means that Boc and Fmoc protection strategies have a huge advantage as 
activation and coupling of Boc or Fmoc protected amino acids are not affected by 
racemisation in this way. 
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Figure 5.1: An oxalone with an alkoxycarbonyl group versus 
an oxalone with an alkyl group 
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5.4 Synthesis of the dipeptide OBzl-Phe-Leu-Fmoc 
As the RSV F protein Fusion peptide contains no troubling residues, the strategy 
decided was to use Fmoc α-amino-protected amino acids in a stepwise synthesis. The 
length of the peptide is the only hurdle to an efficient synthesis and therefore reasons 
as to the decision to use solid phase synthesis to make the entire peptide, but solution 
phase chemistry to synthesis the first dipeptide, will be described in section 5.3.4 
below.  
At all stages, DL amino acids were used (as an enantiomerically pure product was not 
necessary at this preliminary stage) and therefore a racemic mixture of the dipeptide 
would be produced as the end product. Therefore the stereoscopic configurations of 
the molecules are not noted in the reaction schemes.  
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5.5 Materials and Methods 
All reagents were obtained from Fischer Scientific. 
5.5.1 Experimental data analysis 
Analysis of reaction progress was carried out using LC-MS (liquid chromatography 
mass spectrometry), HPLC (high performance liquid chromatography) in MeOH/H2O, 
NMR and TLC (MeOH in DCM).  NMR was carried out by the Eclipse 270 
spectrometer.  Chemical shift data is reported in ppm (parts per million) with the 
protons of the solvent, CDCl3, as an internal reference at 7.25 ppm. J-coupling values 
are given in Hz. Mass spectra were recorded on the Esquire 3000 Plus mass 
spectrometer. HPLC was recorded on the 4.6 x 50 mm Zorbax XDB-C18 column. 
5.5.2 Experimental Method: α-carboxy protection of Fmoc-Phe by formation of 
the ethyl ester 
100 mg Fmoc-Phe was dissolved in 3.00 ml 100 % ethanol and 1.00 ml THF. 49.8 mg 
EDCI coupling reagent was added and the reaction was stirred to completion with 
slowly bubbling nitrogen. The reaction mixture was concentrated to 3.00 ml in vacuo 
then 50.0 ml H2O was added and the solution was extracted with 100 ml ethyl acetate. 
50.0 ml citric acid in water was added and then the extract was washed with 50.0 ml 
saturated brine solution. The solution was dried with MgSO4 and filtered then an 
attempt was made to obtain the product in vacuo. However, because the citric acid was 
added after the first separation the product moved into the aqueous layer. Therefore 
the combined aqueous layers were extracted with 3 x 50.0 ml ethyl acetate. The 
solution was washed with brine, dried over MgSO4 and the solvent evaporated off in 
vacuo. 50.0 ml ethyl acetate was added to the sticky, glassy solid obtained and the 
solution was washed with 20.0 ml saturate potassium carbonate, and then washed with 
20.0 ml brine. This was again dried over MgSO4 and filtered then the product was 
obtained in vacuo. 
5.5.3 Experimental Method: α-amino Boc protection of phenylalanine 
2.00 g DL-Phe was dissolved in 23.8 ml 1, 4-dioxane. 12.1 ml 1N NaOH and 12.1 ml 
H2O were added under ice cooling and the temperature was monitored to ensure no 
excessive temperature rise occurred. 3.08 ml di-tert-butyl dicarbonate was added. This 
was allowed to stir for about 20 minutes and then the ice bath was removed and the 
reaction allowed to reach room temperature. The reaction was stirred to completion 
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(approximately 21 hours) then concentrated on a rotary evaporator to an oil of 5.0 ml.  
20.0 ml ethyl acetate and 20.0 ml heptane were added and evaporation continued. A 
white powder was obtained. [1H NMR (269.72 MHz; CDCl3) δH 7.34-7.28 (m, aromatic, 
3H), 7.25-7.22 (m), 7.17 (d, J = 8.9, aromatic 2H), 5.99 (s, OH, 1H), 4.91 (d, J = 8.1), 
4.62 (d, J = 8.1), 4.39 (s, CH, 1H), 3.15 (qd J = 5.4, 10.8, 5.4, 10.8, CH2, 2H), 1.43 (s, 
(CH3)3, 9H), 1.30 (s), 1.17 (s)]. See Appendix C1. 
5.5.4 Experimental Methods: α-carboxy protection of Boc-Phe  
5.5.4.1 Formation of the benzyl ester using benzyl bromide 
0.800 g Boc-Phe and 2.09 g potassium carbonate were dissolved in 90.0 ml acetone. 
The reaction was stirred and heated using an oil bath with temperature monitoring and 
bubbling nitrogen. 0.700 ml benzyl bromide was added. The solution was heated to 61 
°C and stirred to completion, for approximately 20 hours. This reaction began as a 
heterogeneous solution but progressed overnight to a homogenous saturated solution. 
Another equivalent of benzyl bromide and another equivalent of potassium carbonate 
were added to force the reaction to completion (the LC chromatogram indicated a small 
amount of product was being formed). After an additional 48 hours, the reaction 
solution was Buchner filtered until no potassium carbonate remained. The solvent was 
taken off in vacuo using a PTFE pump due to the HBr co-product.  
5.5.4.2 Formation of the benzyl ester using phenol and PyBop 
4.71 g PyBop was dissolved in 30.0 ml DCM and 2.31ml triethylamine. 2.00 g Boc-Phe 
and 0.851 g phenol were added and the amber solution was left to stir with nitrogen 
bubbling. 40.0 ml H2O was added the solution was extracted then the organic layer 
washed with 50.0 ml brine, dried with MgSO4 and filtered. The solvent was evaporated 
off under vacuum producing amber oil. This was purified via column chromatography, 
with solid phase silica and mobile phase 100 % DCM. The product came off in the first 
ten fractions. The column was flushed with 200 ml DCM, then 5 % MeOH in DCM, 
followed by a 1:1 MeOH:DCM flush and finally 100 % MeOH. 
[1H NMR (269.72 MHz; CDCl3) δH 7.38-7.28 (m, aromatic, 8H), 6.98 (d, J = 8.1, 
aromatic, 2H), 5.05 (s), 4.80 (d, J = 8.1, NH, 1H), 3.22 (d, J = 5.4, CH2, 2H), 2.16 (s), 
1.55 (s, (CH3)3, 10H), 1.43 (s), 0.05 (s)] LCMS m/z 364.2 [M
 + Na]+, 242.0[M - Boc]+, 
705.4 [2M + Na + H]+ . See Appendix C2. 
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5.5.4.3 Formation of the benzyl ester using Phenol and HBTU 
3.43 g HBTU was dissolved in 30.0 ml DCM and 2.31 ml triethylamine. 2.00 g Boc-Phe 
and 0.851 g Phenol were added and the solution was left to stir with nitrogen bubbling. 
The solution was extracted with 50 ml H2O followed by 50.0 ml potassium carbonate 
and a brine wash. The solvent was evaporated off in vacuo and a white solid was 
precipitated. The product was purified via column chromatography (solid phase silica 
and mobile phase DCM), and then elution was with 50.0 ml DCM, 50.0 ml 1 % MeOH 
then 50.0 ml 2 % MeOH. Fractions 11-19 were combined and concentrated in vacuo to 
give 1.52 g white solid product. [1H NMR (269.72 MHz; CDCl3) δH 7.39-7.28 (m), 7.19 
(s, 8H aromatic), 7.00 (d, J = 8.1 aromatic, 2H), 6.97 (s), 5.29 (s), 5.11 (d, J = 8.1), 4.82 
(q, J = 5.4), 3.23 (d, J = 8.1, CH2, 2H), 1.56 (s), 1.45 (s, (CH3)3 9H), 0.06 (s)]. See 
Appendix C3. LCMS 241.9 [M - Boc + H]+, 363.9 [M + Na + H]+, 705.2 [2M + Na +H]+. 
For LC see Appendix C4. 
5.5.4.4 Formation of the benzyl ester using dibenzyl dicarbonate 
1.00 g Boc-Phe was dissolved in 15.0 ml THF. 0.0460 g DMAP was added carefully. 
Finally, 1.08 g dibenzyl dicarbonate was added. The reaction was left to stir to 
completion under bubbling nitrogen overnight. The solution was extracted with 10.0 ml 
ethyl acetate and 10.0 ml saturated potassium carbonate solution, then ethyl acetate 
again. The solution was dried with MgSO4 and filtered before concentrating in vacuo.  
5.5.5 Deprotection: Removal of the Boc group from Boc-Phe-OBzl  
100 mg Boc-Phe-OBzl was dissolved in 0.340 ml DCM in a small reaction tube. 0.230 
ml 4N HCl in 1, 4-dioxane was added. The reaction was left to stir under bubbling 
nitrogen over the afternoon and overnight. 0.0200 ml 4N HCl in 1, 4-dioxane was 
added to force the reaction to completion and the reaction was left to stir to completion. 
2.00 ml diethyl ether was added to precipitate the product and this was filtered under 
vacuum. 20.2 mg white powder product was obtained. The product was analysed by 
LC, see Appendix C5. 
5.5.6 Coupling of Phe-OBzl and Fmoc-Leu 
20.0 mg Phe-OBzl and 0.0380 g HBTU were dissolved in a solution of 0.300 ml DCM 
and 0.0200 ml triethylamine. 0.0350 g Fmoc-Leu was then added and the reaction was 
stirred to completion for 4 hours. A phase separator was used to wash the extract the 
solution with potassium carbonate and 10.0 ml DCM followed by a wash with brine. 
The solution was dried over MgSO4, filtered and concentrated to 10.0 mg oil in vacuo. 
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[1H NMR (269.72 MHz; CDCl3) δH 5.30 (s), 3.48 (s), 2.79 (s), 0.06 (s)] LCMS m/z 577.1 
[M+ + H]+, 599.1 [M+ + Na + H]+. See Appendix C6. 
5.6 Results and Discussion 
5.6.1 Synthesis of Fmoc-Phe-OEthyl 
TLC analysis indicated that the product obtained was either very impure or that the 
EDCI had altered the Fmoc group. It was decided to continue the synthesis using a 
Boc protection strategy, as the cleavage of the Boc protecting group is orthogonal to 
the cleavage of an ester. If Fmoc amino acids continued to be used, it would be 
necessary to carboxy protect using tBu, however the reagents were unavailable. 
5.6.2 Synthesis of Boc-Phe 
Comparison of an NMR sample of product with an NMR taken from a commercial 
sample of Boc-Phe confirmed the product as Boc-Phe as the spectra are identical.  
5.6.3 Synthesis of Boc-Phe-OBzl 
Comparing the four separate routes undertaken to synthesise Boc-Phe-OBzl, the 
purest product with good yield that was obtained was via the route using the coupling 
reagent HBTU with phenol. The NMR spectrum of the product obtained is a clear fit, 
and the liquid chromatography result confirms the purity of the product with only one 
peak at 5.08 minutes. It was concluded that the product should appear at 5.08 minutes 
from the information provided by the LCMS of experiment 5.5.4.2 (the same synthesis 
except PyBop was used as the coupling reagent). This LCMS indicated a significant 
peak at 242.00, corresponding to the Boc group having been removed from the 
product. The removal of the Boc group was caused by the spectrometry and therefore 
it was safe to conclude that a small amount of product was present from reaction 
5.5.5.2. This indication that the peak at 5.08 was the desired product lead to its 
purification in reaction 5.5.5.3.  The reaction using PyBop only produced a small 
amount of product and additional impurities, therefore was not as successful in terms of 
yield of product or as clean as the reaction using HBTU, but was useful in terms of this 
information. The formation of Boc-Phe-OBzl was most successful using HBTU as in 
Scheme 5.8. LC chromatograms for both reactions showed a highly polar peak at 1.6 
minutes, which was likely to have been the ester of the coupling reagent used. This 
was not washed out successfully in reaction 5.5.5.2 as no potassium carbonate wash 
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[75] 
 
was done but this was corrected for work up of reaction 5.5.5.3. 1.52 g product was 
obtained from 2.00 g of starting material, giving a reasonable 59.1% yield.  
The first method attempted, using benzyl bromide, was slow to progress and formed a 
large proportion of a very polar product, likely to involve the acetone used. The problem 
with using acetone as a solvent is that it is also able to react. This was successfully 
removed during evaporation under vacuum leaving two peaks on the LC at 4.7 and 5.2 
minutes, neither being starting material and the second peak only appeared on the 
chromatograms on the sixth analysis. At this point it was obvious from the LCMS from 
5.5.5.2 that neither peak represented the desired product, and the yield was poor.  
The last method attempted was by using dibenzyl dicarbonate, reaction 5.5.5.4. LC 
confirmed a substantial amount of dibenzyl dicarbonate and starting material remained 
unreacted, however a peak at 5.106 minutes indicated some product had formed but 
the reaction did not go any further when left overnight and therefore workup was 
completed to attempt to recover the starting material. 
5.6.4 Deprotection of Boc-Phe-OBzl  
This reaction fully completed, with no starting material remaining. Three peaks were 
visible on the chromatogram before purification. The isolated product was confirmed to 
be pure by LC.  
5.6.5 Coupling of Phe-OBzl to Fmoc-Leu 
The coupling of the first two amino acids of the Fusion peptide produced a number of 
products and would have been difficult to purify. In the first instance, it was expected 
that a mixture of diastereomers would be produced, as the protected phenylalanine 
originated from DL-phenylalanine but the leucine was purely in L configuration from a 
commercial source. However, on the LC chromatogram, where a pair of peaks was 
expected there were two pairs of peaks. To understand this result, after purification, an 
LCMS was taken. The NMR showed little apart from the presence of a few aromatic 
hydrogen atoms. The LCMS clearly confirmed the presence of the desired product with 
the [M+]+ and [M++Na]+ peaks shown, see Appendix C6. 
5.7 Conclusions 
Overall, the formation of the dipeptide was a success with clean reactions on the 
pathway to the product, despite there not being a sufficient quantity of product to 
continue on with to make the full 19 amino acid long fusion peptide. The main aim was 
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to carry out reactions with a view to learning the main principles and practice of solution 
phase peptide synthesis, and this was largely achieved. The numerous methods that 
were attempted to α-carboxy protect Boc-Phe with the benzyl ester group gave a clear 
illustration of how many options there are in peptide synthesis, and this was simply to 
add on one protecting group. The options multiply when one considers other protecting 
groups and alternative protecting group strategies, even for one case of a specific 
peptide. It was always clear that attempting to make the full peptide by solution phase 
chemistry would take months, and that solid phase synthesis would be the obvious 
method of choice, unfortunately not available within Onyx. Other principles, that did not 
need to be taken into account during the specific reactions encountered, such as 
control of racemisation and residue side-chain protection were considered in theory 
regarding the reactions being undertaken. Residue side-chain protection was not an 
issue due to the amino acids required. In fact, very few problems would occur in this 
regard during the remainder of the synthesis, as none of the residues involved would 
be problematic.  
5.8 Further Work 
The obvious next step would be synthesis of the Fusion Peptide using stepwise SPPS 
methods. This will be carried out on a resin using a microwave synthesiser within 
Durham University, which will greatly speed up the rate of protection, coupling and 
deprotection to a few days to complete the peptide. Synthesis from 3’ to 5’ would be 
advantageous as useful experimental labels could be readily added to phenylalanine 
such as a fluorescent label, in order to view the peptide’s interaction with a synthesised 
membrane and/or with cell membranes. Methods of characterisation will be 
undertaken; including mass spectrometry to check the mass of the peptide is correct 
and circular dichroism to assess the level of secondary structure. It is predicted from 
the sequence that this hydrophobic peptide will form an α-helix. This could create 
problems during solid phase synthesis as the helix will begin to form at a certain point 
(it is likely this will occur at the LeuLeu section, if synthesised from 3’ to 5’). At this 
point, half of the partially made peptide will be taken forward whilst it is analysed by 
mass spectrometry to assess whether steric hindrance is affecting the process. In fact, 
at three intervals during the synthesis the peptide will need to be checked by mass 
spectrometry.  
Residue specific considerations are only an issue for the serine residues in the 
sequence, whose side chains may need to be protected in order to prevent them 
forming disulphide bonds.  
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[77] 
 
In contrast to the solution peptide chemistry performed above, where only the 
principles of peptide chemistry were the concern, in the synthesis of the full peptide 
maintaining stereochemical integrity will be an important issue. The two mechanisms of 
racemisation are outlined above in section 5.3.6. If there is 1 % conversion from L to D 
configuration at each coupling stage for the Fusion peptide then this would mean 19 % 
of the products would be D configured. HPLC may be used to check for D and L 
diastereomers (they will appear as pairs of peaks, as in the coupling carried out to 
make the dipeptide above).  
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Chapter Six: Overall Discussion of Results 
M2-1 protein was made ready for crystal trials. This was indicated by gel filtration 
chromatography analysis to be in the form of a tetramer, but this analysis should be 
repeated to include a protein standard over 90 kDa. This was sent for crystal trials by 
the Durham University in-house service. Optimisation of the purification protocol was a 
success despite difficulties in cleaving the protein from GST and in purifying M2-1 by 
FPLC anion exchange chromatography. As during the last attempt at crystallisation 
there was difficulty finding the right conditions for crystal growth, a scale up of the 
expression and purification is recommended to give more protein to work with, which 
could easily be achieved with a larger volume of glutathione sepharose beads and a 
higher concentration of salt (1 M up from 150 mm in the cleavage buffer) may give a 
higher yield of protein.3 Circular dichroism has been carried out previously to obtain 
information on the secondary structure of M2-1 in solution and the data was published 
in July 2009.3 It would be useful to obtain data on the protein obtained from this project 
for comparison and in order to repeat the experiment, expecting to confirm the results. 
This previous study found the far-UV CD spectrum was similar to other highly 
structured proteins with estimations of secondary structure obtained as 38 % α-helices, 
12 % β-sheets, 40 % random coils and 10 % turns. Therefore it would be expected that 
a repeat of this experiment would show the protein to be highly α-helical. The methods 
of expression and purification method were subtly different from the 2009 paper, but 
this should not affect protein integrity. Comparing the two methods, the major 
difference is the use of a thrombin cleavage site between GST and M2-1 instead of 
using 3C or PreScission protease. PreScission protease has the advantage that it is 
most active at 4 °C and therefore cleavage can occur at a temperature at which the 
protein will remain stable. Thrombin is most active at 22 °C and also it gives more 
unspecific cleavage, in general, when compared with PreScission. In a comparison of 
GST-Fusion proteases PreScission protease was the most effective in terms of yield of 
protein by a sizeable margin when viewed on an SDS gel.76 It should be noted that this 
study was carried out for the company that sells PreScission protease, however all of 
the proteases compared in the study were sold by the same company. 
It was an aim of this project to successfully clone and express a soluble form of the 
Fusion Protein using the Baculovirus Expression System from Invitrogen. 
Unfortunately, initial cloning of FSol into a primary vector proved difficult and has not 
yet been achieved. Attempts were made via conventional ligation dependant cloning 
and cloning using the topoisomerase enzyme with a commercial kit but all were to 
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[79] 
 
similar levels of success.  All materials used were re-checked for activity, such as the 
restriction enzymes used and the topoisomerase cloning kits as detailed in Chapter 
Two. There are many variables to be considered that may have contributed to the 
difficulty in cloning the soluble fragment of F. It is possible that UV damage occurred to 
the plasmid and/or fragment during extraction of the bands from the gel. Possible UV 
damage to DNA includes pyrimidine dimer formation, destruction of bases, backbone 
breakdown and cross-linking. It is possible that this could interfere with the efficiency of 
ligation. If this occurred to the plasmid during gel extraction then this would explain why 
ligation into pMIB/V5-His did not work during any attempt at the initial strategy or during 
subcloning into this plasmid after cloning into a TOPO vector (see below). The gel was 
only exposed for a short amount of time, however this has still been shown to cause 
significant damage at around 300 nm UV and be a factor in reduction of cloning and 
transformation efficiency.77 It has been shown that addition of 1 mmol/L guanosine in 
the running buffer protected the DNA from damage to a significant extent and this study 
determined that exposure of 20-45 seconds using a standard visualiser could leave as 
little as 1 % of the DNA fully intact.77 A wavelength of around 254 nm causes the most 
damage compared to those of higher wavelengths.78 There have been reports of UV 
damage being a likely cause of downstream cloning problems as early as the 1970s 
but the problem is often still thought to be a minor consideration.78 Relatively recent 
development of alternative visualisation technology (for example the Clare Chemical 
Dark Reader which uses visible light and filters) means this is not necessary and the 
use of UV, or at least shortwave UV light could be avoided.  
The problem appeared to occur at the point of ligation and/or transformation. If the 
problem was with the ligation step, this would explain why a couple of positive colonies 
were obtained when topoisomerase cloning was carried out and none with 
conventional ligation-dependant cloning. This was still a very low level of success. The 
TOPO cloning procedures were attempted on other DNA constructs for separate 
experiments successfully and therefore there is no fault with the topoisomerase 
enzyme and as using this method did not solve the problem it is safe to assume there 
is also no problem with the original DNA ligase used for the conventional cloning 
technique. Therefore there is either fault in the design of the ligating ends, and 
therefore problems at the restriction stage, or there are problems in transforming the 
product into competent cells. The commercial competent cells were double checked by 
transforming them with a separate construct, the gene YcaO from E. coli (a gift from Dr 
R. Dorazi, University of Durham), in the Champion vector successfully. Therefore the 
problem most likely arose in ligation. 
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The difficulty with cloning F is most likely to have come from the ability of the ligase to 
ligate the ends of the DNA fragment into the appropriate restricted sites of the new 
vector. Also, during the ligation if the molar ratio of the plasmid to target DNA is too 
high then the ligation may give a high number of circular empty plasmids and if the ratio 
is too low then an excess of linear and circular homo and heteropolymers of varying 
sizes, orientations and compositions will be produced. The presence of 5’ phosphates 
recircularising the DNA has been accounted for by using Calf Intestinal Alkaline 
Phosphatase. Options for improvement and further work on cloning and expression of 
FSol are detailed in Chapter Seven. 
The synthesis of the 19 amino acid long Fusion Peptide should be straightforward by 
solid phase synthesis techniques and could take as little as a week (Dr S. Cobb, 
personal communication), with structural characterisation to follow after purification, as 
discussed in Chapter Five. Although the heptad repeats have been characterised by 
crystallography before, this has not been the case for the fusion peptide, which is 
predicted to form a hydrophobic α-helix.  
Experiments targeting F to specific cellular organelles were successful, showing that 
the constructs do localise to the correct respective organelles. The activity of the 
construct FSTOP was of interest as the images (see Fig. 3.3(d)) showed that absence of 
the C-terminal domain did not affect localisation of the Fusion protein to the membrane. 
Therefore another region of the protein must be responsible, likely the Transmembrane 
Domain itself. The Fusion protein imaging experiments to analyse at what point F 
interacts with M in order for virion assembly to occur were moderately successful, 
showing that F does not first interact with M in any of the organelles but rather at or 
before reaching the plasma membrane. Massive damage was caused to the cell 
structure during localisation of F and M using wild type F.  It was noted in the construct 
that was designed to transport throughout the organelles in the normal order of 
glycoprotein processing that F finally localised with M at the Golgi apparatus, but as 
this construct was recycled it is likely that the interaction occurred at the plasma 
membrane and M was taken with F through the cycle. M was not localised at the Golgi 
apparatus with an F construct that was designed to localise to the Golgi apparatus 
only. It has not been possible as yet to ascertain whether this interaction occurs at or 
before reaching the plasma membrane. The Golgi apparatus is the last organelle that 
the protein locates to and is processed by before locating to the membrane.  
Relating all aspects of these results to each other, progress has been made towards 
optimised production of the two protein constructs and the fusion peptide, even the 
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[81] 
 
difficulties found in expressing a soluble form of the F protein only adds to the 
knowledge of how and how not to clone this particular fragment, and will aid the 
formulation of a new strategy. The localisation experiments with F and M proteins are a 
part of characterising the activity of these vital viral proteins within the cellular 
environment, as the main aim is indeed structural information and crystal structures of 
F and M2-1 but this line of research also aims to obtain useful biochemical information 
about their activity, specifically from localisation studies and experiments on lipid-
protein interactions. 
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Chapter Seven: Conclusions and Recommendations 
 
The aims of this project on preliminary analysis of viral proteins of human respiratory 
syncytial virus were to clone, express and purify the soluble form of the Fusion protein; 
to express, purify and begin crystallography trials on M2-1 protein; to synthesis the 
Fusion peptide by chemical methods; and to visualise the co-localisation of the F 
protein with M in mammalian cells. The conclusions made from this project are detailed 
below, along with recommendations to further this work and the potential use of 
structural information on F and M2-1 is described. 
7.1 M2-1 Expression and purification 
The M2-1 protein can now be expressed and purified successfully and at a level 
suitable for crystallographic trials. The purification protocol was optimised and a 
procedure utilising glutathione sepharose beads was found to be the most effective in 
terms of yield of protein and purity. Mass spectroscopic analysis has yet to be carried 
out on M2-1 obtained to confirm accurately the molecular mass of the product 
obtained. Purification on a MonoQ anion exchange column was not a success as the 
protein failed to elute from the column. Therefore a resin with lower affinity for M2-1 
may improve this. It is also possible that the monomer and oligomers of M2-1 have 
different affinities for the MonoQ column resin, and therefore whilst the initial sample 
purified well at pH 8 the next and larger fraction passed straight through the column or 
stuck to the column at the same pH. However, purification by size using a gel filtration 
column was a success and M2-1 was obtained as a single species, in this case a 
tetramer confirming previous observations.3 On a previous occasion when pure protein 
was obtained, there were difficulties in determining the optimum conditions for 
crystallisation (Dr V. Money, personal communication). In addition, the solution 
containing M2-1 was quite viscous and this meant difficulties in crystal trials, but this is 
not the case from the results of purifications carried out during this project. Initial crystal 
trial conditions were attempted using an Opti-Salts Suite kit from Qiagen.79 To date, no 
crystals have been obtained but the full range of crystal forming conditions have not yet 
been exploited. M2-1 protein will also undergo circular dichroism analysis, in order to 
obtain data to compare against references and gain some knowledge of M2-1’s 
secondary structure, and this will be compared against previous data obtained in 
2009.3  
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7.2 FSol cloning 
Cloning of the FSol fragment, or rather the extra-cellular F1 domain, proved to be 
difficult, despite attempting two separate strategies that usually produce excellent 
results were utilised. Due to insufficient time, a new strategy was not attempted after 
topoisomerase I cloning. The commercial cloning kits were double checked by 
successful cloning of a different non-related target, the gene YcaO from E. coli (a gift 
from Dr R. Dorazi, University of Durham). There could be an incompatibility for cloning 
in the design of the construct and/or primers used as. Recommendations for future 
attempts include double-checking every small aspect of the cloning strategy, alteration 
of the FSol construct (even if this means obtaining a mutated protein) and attempting 
an alternative strategy, possibly with a commercial kit to give reliability and 
reproducibility. It may be a good idea for future work to simply attempt restriction using 
different restriction sites and enzymes, to create different ends. Other research groups 
have managed to clone constructs of F, but notably not a full-length soluble form.  For 
example, a 1999 paper on the interaction of F with RhoA80 successfully produced the 
extracellular domain and deletion mutants thereof for interaction studies. They did this 
using restriction sites EcoR1 and BamH1 of the pAS2-BD vector from Clontech.80  
Alternative procedures are discussed below.  
Alternative ligation independent cloning (LIC) methods (by recombination or producing 
and annealing overhangs) could be attempted, that are therefore independent of the 
insert sequence.81 These methods, of which topoisomerase cloning is one, often add 
extra complexity to the procedure, for example requiring additional sequences at the 5’ 
end of the primers that must match the vector sequences. For cloning with no enzyme 
mediation, these methods often also require four pairs of primers in order to replace 
conventional ligation with PCR mediated cloning.82 There is also enzyme-mediated 
LIC, where after the additional sequences are designed on the 5’ of the primers, the 
fragment is treated with one of a number of enzymes (such as T4 DNA polymerase, 
exonuclease III or Uracil DNA glycosylase) to give sticky ends in order to insert it into a 
suitable vector by hybridising with the complementary sticky ends of the vector.82, 83 A 
broad review of ligation independent cloning methods along with details of a highly 
efficient enzymatic cloning procedure describing the In-FusionTM enzyme (Clontech) 
can be found in Berrow et al. 2007,81 and in the Clontech In-Fusion cloning 
handbooks.84 
In order to increase the chance of ligation of all available fragments and vectors in the 
reaction, it could be an idea to add the original restriction enzymes, HindIII and XbaI, to 
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the ligation reaction. This would be advantageous as, providing that after ligation the 
restriction sites were not usually reformed, then the presence of the restriction 
enzymes would restrict any self-ligated plasmid and increase the number of 
recombinants. The equilibrium would be driven to produce the desired recombinant 
plasmid. Circular DNAs produce more transformants than linear DNA and therefore the 
colonies successfully transformed with the recombinant plasmid should outnumber 
those with plasmid lacking the desired cloned insert. Despite the advantages in terms 
of cost and of not needing to add special sequences to the ends of the primers, it is 
true that blunt-end cloning is generally less efficient than sticky-end cloning and there is 
an increase in the number of vectors self-ligating.82 Sticky-end cloning may be the 
option that would maximise the efficiency of this cloning reaction. However, the 
topoisomerase cloning using the Invitrogen Champion Cloning kit uses a sticky end 
approach in order to give directional cloning and this failed to product positive results. 
Sticky end approaches also have problems with the ability of the restriction enzymes to 
efficiently cut the DNA at the required sites, especially if those sites are at the 5’ end of 
double stranded PCR product. However, one way of avoiding this would be to use a 
technique called Autosticky PCR (AS-PCR) that uses two primers containing 
tetrathydrofuran-derivative abasic sites that stall DNA polymerase, giving PCR 
products with different single stranded 5’ overhangs at both ends- giving sticky ends for 
two restriction sites. These products are then directionally cloned into appropriately 
restricted plasmids.82  
It could be more effective to use synthetic linkers 8-16 bases long encoding restriction 
sites, ligating them to the blunt ended fragment to give cohesive ends for cloning.68 A 
detailed protocol for this can be found in Sambrook and Russell, 2001.68 However, this 
relatively old technique is usually only used now when a necessary restriction site is 
missing from the DNA fragment to be cloned, or when the sequence of the DNA is 
unknown. 
Further ahead, research questions about the mode action of the fusion protein include 
ascertaining how many Fusion Proteins are required to form a functional fusion pore 
and also how many fusion pores are required to give full infectivity. In depth 
mathematical modelling in combination with lipid membrane interaction experiments 
would be necessary to answer these questions. 
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7.3 Co-localisation of F and M 
The IFA imaging experiments were successful, despite the preliminary experiments 
requiring high exposure times and therefore giving poor images. It was demonstrated 
that the constructs that targeted or retained the F protein in sub-cellular compartments 
other than the plasma membrane expressed and functioned as predicted. When co-
expressed with the M protein we only observed co-localisation at a later stage of the 
transport of F i.e. post Golgi body.  We can conclude this as the M protein did not co-
localise with F when F was retained in the ER or Golgi.  The F and M did co-localise at 
the plasma membrane and within endosomes and Golgi as a result of recycling from 
the membrane.  We can tentatively conclude failure to co-localise at the early stage 
was not due to the modification of the cytoplasmic tail as the later constructs were 
similarly modified, notably the F construct with the ER retention signal disrupted acts as 
unmodified F.  Co-localisation of F and M was also not dependent on the presence of 
the cytoplasmic tail; however we did not test if the cytoplasmic tail minus construct was 
directed to lipid rafts as was the wild type F.  
However, it has not been possible as yet to ascertain whether the F/M interaction 
occurs at or before reaching the plasma membrane via the normal transport pathway. 
This could be done if a larger time frame was available in order to undertake electron 
microscopy studies of the transport of proteins between the membrane and the Golgi 
apparatus. The Golgi is the last organelle that the protein locates to, where it is 
modified by proteolytic cleavage to mature F to before locating to the membrane. This 
would involve high pressure freezing of cell samples (to preserve ultrastructure without 
creating ice crystal damage) before labelling with gold-labelled antibodies specific to M 
and to F. To distinguish between M and F antibodies the gold labels would be of 
different diameters for F and for M, which could be distinguished using an electron 
microscope. A project such as this would be complex and take a considerable length of 
time.  
One significant observation was that when F and M were co-expressed the levels of M 
produced were significantly greater than if M was expressed alone.  This was not due 
to the levels of DNA transfected when two plasmids were used as an empty vector was 
usually added to the M only mix to normalise DNA levels.  The observed effect was of 
significant damage to the membranes resulting in cell disruption.  Even when there was 
no observed interaction between F and M at the ER or Golgi, the result was the same, 
significant damage to the membrane.  Thus it would be inappropriate to fully dismiss 
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any interaction between ER or Golgi trapped F and M, but currently we cannot provide 
an adequate explanation of what that interaction is.   
Further work using an alternative expression system, such as a lentiviral based one, 
with inducible promoters to control expression of the proteins and integration of the 
genomic DNA into the target cell genome giving stable expression, could be 
employed.85 Changing the transmembrane domain should also be considered as 
cytoplasmic tailless F interacted with M. 
7.4 Chemical synthesis of the Fusion Peptide 
Synthesis of the Fusion Peptide using solid phase techniques should be 
straightforward as detailed in Chapter Five.  Future studies on the activity of the fusion 
protein should include crystallisation and studies into the peptide’s interaction with 
lipids in bilayers, i.e. membranes. The question to answer would be is the fusion 
peptide able to locate and interact with the cell lipid membrane on its own or does it 
require other parts of the whole protein to do this? It would be useful to conduct 
experiments on both artificially synthesised lipid membranes, liposomes and on 
mammalian cells using immunofluorescence studies and electron microscopy. 
7.5 Validity and reliability of results 
A point on the validity of any results obtained from studies on FSol and the fusion 
peptide is that as they are separate constructs, any results could not be wholly applied 
to conclusions about the full protein, although they would provide a very good 
indication of the full structure. It would be ideal to be able to crystallise the protein in 
both inactive and active conformations. These have been issues with previous studies 
described in Chapter One, for example, the NDV homology model of F and the crystal 
structure of F core. It should be noted however that if F protein was able to be 
expressed in Baculovirus in insect cells (once cloning was successful), then this should 
reproduce most post-translational modifications that would occur in a mammalian cell, 
such as cleavage of F1 from F2. Expressing F protein in mammalian cells could be 
investigated but first cloning needs to be achieved. Any structural information gained or 
knowledge on their activity with lipids will be at the least an additional piece of 
information, but an important piece for biological understanding and future inhibitor 
development. Any structural information gained from crystallography of M2-1 would 
indeed be valid as the protein was obtained as a whole, with no hydrophobic sections 
or disulphide bridges to make purification difficult. M2-1 does form oligomers and of 
course this would need to be taken into account during crystallography studies.  
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7.6 In the Future: Routes to inhibition of the F and M2-1 proteins 
functionality 
Concerning studies into the inhibition of the F protein’s fusion ability, it was found that 
using peptides that represent the heptad repeats results in the most success in terms 
of specific, targeted and complete inhibition of F activity and therefore viral infectivity.38 
Peptides synthesised from the two heptad repeats have been shown to have an 
inhibitory affect on the protein’s activity. Peptides from HR1 can also prevent syncytia 
formation.15 The mode of action is proposed to be by interference by the peptide on the 
interaction between HR2 and HR1 during the conformational change that occurs to 
facilitate drawing together of opposing membranes, which is crucial for infectivity. It is 
likely this interference would occur between the peptide and the α-helical N terminus of 
HR2.15 There are a number of potential molecules developed that could inhibit F’s 
fusion activity or its processing.15 As a proof of principle in developing molecules that 
inhibit fusion two peptides synthesised from HIV-1 gp41’s (the equivalent of F) heptad 
repeats, DP-107 and DP-178, are potent inhibitors of HIV-1.86 The sequences they 
were synthesised from correspond to the heptad repeat regions of the protein. 
Therefore the study was extended to DP-like peptides synthesised from other related 
viruses, including hRSV, as structurally the proteins share a common mechanism in 
mediating membrane fusion. It was found that the DP-178-like inhibitors (based on 
HR1) were highly potent in blocking syncytia formation, and were very specific for their 
virus of origin. Only the inhibitors of hPIV3 were cross reactive with hRSV and MuV but 
this required thirty times the usual concentration.86 The most important example of this 
is however the peptide T20, which has been developed from the C-terminal heptad 
repeat of gp41, into a successful drug, Enfuvirtide, against HIV-1 (marketed also as 
Fuzeon). Studies into this mode of inhibition could be the most likely route to drug 
design, especially considering this strategy has been a success against HIV-1’s gp41 
fusion protein.17, 18 It only accentuates the importance of obtaining an accurate crystal 
structure of hRSV F as exact knowledge of the protein’s conformation and intra-domain 
interactions between HR1 and HR2 would aid in the design of the inhibitor molecule. In 
this respect, it would of course be ideal to aim to obtain not only the crystal structure of 
hRSV F, but also that of F with inhibitors bound. There is one such structural study 
which showed an inhibitor, derived from the heptad repeats of RSV F (TMC353121), 
bound to the hexameric core.38 This inhibitor did not prevent the interaction between 
the protein’s heptad repeats directly, but instead altered the conformation of HR2.38 
However, this structure is limited to the inhibitor molecule and to the heptad repeat 
peptides and not the complete protein.38 
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A recent study into M2-1 inhibition concentrated upon the zinc finger motif. Compounds 
targeting a zinc finger have successfully inhibited other viral nucleocapsid proteins, 
including HIV-1 and MuLV proteins. In general, it is better to inhibit an intracellular 
protein than an extracellular one as altering surface proteins risks the host immune 
response to the virus being adversely altered also. However, this study involved the 
use of a very general chemical inhibitor that cross-links cysteine residues, which are 
obviously present in many proteins of a cell not only the M2-1 protein.87 Therefore, with 
few studies into specific inhibition of the M2-1 protein available, structural information 
would be an excellent start.  
Small steps have been made in this project towards structural characterisation and 
therefore towards successful design of inhibitor molecules targeting the F and M2-1 
proteins of hRSV. The suggestions for further work in this chapter should be carried out 
in order to not only achieve cloning and expression but especially to succeed in the aim 
of obtaining crystal structures for both proteins. Research into hRSV has been going on 
for decades without positive results for a vaccine or effective drug molecule, making 
accurate structural information on the vital F and M2-1 proteins very important indeed 
for careful inhibitor design. 
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Appendix A: Plasmid Maps 
A1. pMIB/V5-His 
 
 
  
HBM Honeybee melittin secretion signal 
V5 epitope V5 epitope 
6xHis Polyhistidine (6x) tag 
Stop Stop codon 
EM7 EM7 promoter 
POpIE1 OpIE1 Promoter 
pUC ori pUC origin 
POpIE2 Reverse priming site 
P OpIE2 pA Polyadenylation sequence 
Ampicillin Ampicillin resistance gene 
Blasticidin Blasticidin resistance gene 
 
Figure A1: Features of the pMIB/V5-His plasmid including restriction sites of the multiple 
cloning site. Taken from the Invitrogen pMIB/V5-His A, B, and C Vector Kit User Manual.
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A2. pET100/D-TOPO® 
lacO Lac operator 
RBS Ribosome binding site 
ATG Initiation codon ATG 
6x His Polyhistidine (6x) tag 
T7 T7 promoter and priming site 
Xpress
TM
 epitope  
EK EK recognition site 
T7 term T7 transcription termination region 
lacI lacI origin of replication (complementary strand) 
Ampicillin Ampicillin resistance gene 
Kanamycin Kanamycin resistance gene 
pBR322 ori pBR322 origin 
rop ROP origin of replication (complementary strand) 
Figure A2: Features of the pET100/D-TOPO plasmid from the Invitrogen 
Champion pET Directional TOPO Expression Kit. Taken from the 
Champion™ pET Directional TOPO
® 
Expression Kits User Manual.
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A3. pCR® 4Blunt-TOPO® 
M13R M13 Reverse Priming site 
LacZ LacZα initiation codon 
T3 T3 priming site 
T7 T7 priming site 
M13F M13 Forward priming site 
LacZα-ccdB LacZα-ccdb gene fusion. The expression of this is disrupted if a blunt 
ended PCR product is ligated into the vector, ensuring growth of only 
positive colonies. 
pUC ori pUC origin 
PLac Lac promoter 
Ampicillin Ampicillin promoter and resistance gene 
Kanamycin Kanamycin promoter and resistance gene 
M13R T3 LacZ 
P
s
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Figure A3: Features of the pCR 4Blunt-TOPO vector from the Invitrogen Zero Blunt
®
 
TOPO
®
 PCR Cloning Kit for Sequencing, including restriction sites. Adapted from Zero 
Blunt TOPO PCR Cloning Kit for Sequencing User Manual.
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M13R M13 Reverse Priming site 
LacZ LacZα initiation codon 
T3 T3 priming site 
T7 T7 priming site 
M13F M13 Forward priming site 
LacZα-
ccdB 
LacZα-ccdb gene fusion. The expression of this is disrupted if a 
blunt ended PCR product is ligated into the vector, ensuring growth 
of only positive colonies. 
pUC ori pUC origin 
PLac Lac promoter 
Ampicillin Ampicillin promoter and resistance gene 
Kanamycin Kanamycin promoter and resistance gene 
 Figure A3: Features of the pCR 4Blunt-TOPO vector from the Invitrogen Zero Blunt
®
 
TOPO
®
 PCR Cloning Kit for Sequencing, including restriction sites. Adapted from Zero 
Blunt TOPO PCR Cloning Kit for Sequencing User Manual.
67 
Helen Bache     Preliminary Analysis of Vital Proteins of the Human Respiratory Syncytial Virus 
[92] 
 
Appendix B: Sequences and Primers 
B1. Sequence of F with the Fusion Peptide in purple, the signal peptide and 
transmembrane domain in teal: 
1 MELLILKANAI  11 TTILTAVTFC  21 FASGQNITEE  31 FYQSTCSAVS 
41 KGYLSALRTG  51 WYTSVITIEL   61 SNIKKNKCNG  71 TDAKIKLIKQ  
81 ELDKYKNAVT 91 ELQLLMQSTP 101 ATNNRARREL 111 PRFMNYTLNN 
121 AKKTNVTLSK  131 KRKRRFLGFL  141 LGVGSAIASG  151 VAVS KVLHLE  
161 GEVNKIKSAL  171 LSTNKAVVSL  181 SNGVSVLTSK  191 VLDLKNYIDK 
201 QLLPIVNKQS 211 CSISNIETVI  221 EFQQKNNRLL  231 EITREFSVNA   
241 GVTTPVSTYM  251 LTNSELLSLI  261 NDMPITNDQK  271 KLMSNNVQIV  
281 RQQSYSIMSI  291 IKEEVLAYVV   301 QLPLYGVIDT  311 PCWKLHTSPL  
321 CTTNTKEGSN  331 ICLTRTDRGW  341 YCDNAGSVSF  351 FPQAETCKVQ   
361 SNRVFCDTMN 371 SLTLPSEVNL  381 CNVDIFNPKY  391 DCKIMTSKTD  
401 VSSSVITSLG  411 AIVSCYGKTK   421 CTASNKNRGI  431 IKTFSNGCDY  
441 VSNKGVDTVS  451 VGNTLYYVNK  461 QEGKSLYVKG  471 EPIINFYDPL 
481 VFPSDEFDAS  491 ISQVNEKINQ  501 SLAFIRKSDE  511 LLHNVNAVKS  
521 TTN IMITTII  531 IVIIVILLSL   541 IAVGLLLYCK  551 ARSTPVTLSK  
561 DQLSGINNIA  571 FSN 
 
B2. Sequence of M2-1: 
 1 MSRRNPCKFE  11 IRGHCLNGRR  21 CHYSHNYFEW 31 PPHALLVRGN  
41 FMLNKILKSM  51 DKSIDTLSEI  61 SGAAELDRTE   71 EYALGIVGVL  
81 ESYIGSINNI 91 TKQSACVAMS 101 LLIEINSDD  111 IKKLRDNEEP  
121 NSPKIRVYNT  131 VISYIESNRK  141 NNKQITHLLK  151 RLPADVLKKT  
161 KNTLDIHKS  171 ITISNPKEST  181 VNDQNDQTKN 191 NDITG  
 
B3. Primers: 
FSOLFORHINDIII: GGC ATG CTA AGC TTA CAA AAC ATC ACT GAA GAA TTT TAT C 
FSOLREVXBA1: C GAA GGG CCC TCT AGA ATT TGT GGT GGA TTT AAC AGC 
 
B4. Topoisomerase cloning forward primer: 
TOPOFSOLFORHINDIII: CAC CAA GCT TAC AAA ACA TCA CTG AAG AAT TTT ATC 
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Appendix C: Experimental analysis spectra 
C1. Boc-Phe 
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7.22 (m), 7.17 (d, J = 8.9, aromatic 2H), 5.99 (s, OH, 1H), 4.91 (d, J = 8.1), 4.62 (d, J = 8.1), 
4.39 (s, CH, 1H), 3.15 (qd J = 5.4, 10.8, 5.4, 10.8, CH2, 2H), 1.43 (s, (CH3)3, 9H), 1.30 (s), 
1.17 (s) 
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Figure C1: Boc-Phe 1H NMR (269.72 MHz; CDCl3) δH 7.34-7.28 (m, aromatic, 3H), 
7.25-7.22 (m), 7.17 (d, J = 8.9, aromatic 2H), 5.99 (s, OH, 1H), 4.91 (d, J = 8.1), 
4.62 (d, J = 8.1), 4.39 (s, CH, 1H), 3.15 (qd J = 5.4, 10.8, 5.4, 10.8, CH2, 2H), 1.43 
(s, (CH3)3, 9H), 1.30 (s), 1.17 (s) 
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C2. Boc-Phe-OBzl produced via Scheme 5.7 
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C3. Boc-Phe-OBzl produce via Scheme 5.8 
 
 
Figure C3: Boc-Phe-OBzl produce via scheme 5.8: 
1
H NMR (269.72 MHz; CDCl3) δH 7.39-
7.28 (m), 7.19 (s, 8H aromatic), 7.00 (d, J = 8.1 aromatic, 2H), 6.97 (s), 5.29 (s), 5.11 (d, J = 
8.1), 4.82 (q, J = 5.4), 3.23 (d, J = 8.1, CH2, 2H), 1.56 (s), 1.45 (s, (CH3)3 9H), 0.06 (s) 
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C4. Boc-Phe-OBzl produced via Scheme 5.8 
 
 
 
C5. Deprotection of Boc-Phe. 
 
  
Figure C4: Boc-Phe-OBzl produced via scheme 5.8: Liquid Chromatography 
chromatogram showing completeness of reaction and purity of product 
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Figure C5: Deprotection of Boc-Phe: Liquid chromatography chromatogram 
showing completeness of reaction and purity of product 
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C6. OBzl-Phe-Leu-Fmoc 
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